Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31996411,sodium excretion,Dietary sodium restriction reduced sodium excretion from 160 to 64 mmol per day.,A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31996411/),[mM] / [d],160,839,DB00999,Hydrochlorothiazide
,6689277,Maximum concentrations,"Maximum concentrations of mepindolol in the plasma of 25 ng ml-1 were achieved 1.6 h after both treatments and the half-life of disposition was calculated to be 4-5 h, being somewhat longer after the combination tablet.",Pharmacokinetics of mepindolol administered alone and in combination with hydrochlorothiazide--a bioequivalence study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6689277/),[ng] / [ml],25,1938,DB00999,Hydrochlorothiazide
,6689277,half-life of disposition,"Maximum concentrations of mepindolol in the plasma of 25 ng ml-1 were achieved 1.6 h after both treatments and the half-life of disposition was calculated to be 4-5 h, being somewhat longer after the combination tablet.",Pharmacokinetics of mepindolol administered alone and in combination with hydrochlorothiazide--a bioequivalence study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6689277/),h,4-5,1939,DB00999,Hydrochlorothiazide
,6689277,half-life of renal excretion,The half-life of renal excretion was 3 h.,Pharmacokinetics of mepindolol administered alone and in combination with hydrochlorothiazide--a bioequivalence study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6689277/),h,3,1940,DB00999,Hydrochlorothiazide
,25575509,flow rate,"The mobile phase consisted of 0.1% formic acid in ammonium acetate buffer (0.02 M, pH 3.5) and methanol (25:75, v/v), flowing through XBridge BEH (50 × 2.1 mm ID, 5 µm) C18 column, at a flow rate of 0.6 mL min(-1).","Simultaneous Determination of Aliskiren Hemifumarate, Amlodipine Besylate and Hydrochlorothiazide in Spiked Human Plasma Using UPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25575509/),[ml] / [min],0.6,2283,DB00999,Hydrochlorothiazide
,12270622,relative bioavailability,"The relative bioavailability of the moulded tablet administered as a lozenge and as an oral tablet was 106.2+/-30.9% and 89.4+/-25.9%, respectively, in relation to the conventional tablet formulation.",Bioavailability of hydrochlorothiazide from isomalt-based moulded tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12270622/),%,106.2,2432,DB00999,Hydrochlorothiazide
,12270622,relative bioavailability,"The relative bioavailability of the moulded tablet administered as a lozenge and as an oral tablet was 106.2+/-30.9% and 89.4+/-25.9%, respectively, in relation to the conventional tablet formulation.",Bioavailability of hydrochlorothiazide from isomalt-based moulded tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12270622/),%,89.4,2433,DB00999,Hydrochlorothiazide
,31396085,m/,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,445.20,12429,DB00999,Hydrochlorothiazide
,31396085,m/,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,148.90,12430,DB00999,Hydrochlorothiazide
,31396085,m/z,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,451.40,12431,DB00999,Hydrochlorothiazide
,31396085,m/z,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,154.30,12432,DB00999,Hydrochlorothiazide
,31396085,m/z,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,295.80,12433,DB00999,Hydrochlorothiazide
,31396085,m/z,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,205.10,12434,DB00999,Hydrochlorothiazide
,31396085,m/z,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,298.90,12435,DB00999,Hydrochlorothiazide
,31396085,m/z,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,206.30,12436,DB00999,Hydrochlorothiazide
,7094977,distribution half-life,"After intravenous injection of allopurinol 300 mg the plasma disappearance was biexponential, with a mean distribution half-life of 2.32 +/- 1.08 min (mean +/- SD) and an elimination half-life of 47.8 +/- 10.6 min.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),min,2.32,20022,DB00999,Hydrochlorothiazide
,7094977,elimination half-life,"After intravenous injection of allopurinol 300 mg the plasma disappearance was biexponential, with a mean distribution half-life of 2.32 +/- 1.08 min (mean +/- SD) and an elimination half-life of 47.8 +/- 10.6 min.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),min,47.8,20023,DB00999,Hydrochlorothiazide
,7094977,total clearance,"The total clearance of allopurinol was 11.37 +/- 2.70 ml/min/kg, whereas its renal clearance was only 1.73 +/- 0.79 ml/min/kg.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),[ml] / [kg·min],11.37,20024,DB00999,Hydrochlorothiazide
,7094977,renal clearance,"The total clearance of allopurinol was 11.37 +/- 2.70 ml/min/kg, whereas its renal clearance was only 1.73 +/- 0.79 ml/min/kg.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),[ml] / [kg·min],1.73,20025,DB00999,Hydrochlorothiazide
,7094977,half-life,Oxipurinol disappeared monoexponentially from plasma with a mean half-life of 12.2 +/- 2.6 h.,Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),h,12.2,20026,DB00999,Hydrochlorothiazide
,7094977,renal clearance,Its renal clearance was 0.42 +/- 0.091 ml/min/kg.,Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),[ml] / [kg·min],0.42,20027,DB00999,Hydrochlorothiazide
,7094977,peak plasma concentration,After oral administration of allopurinol 300 mg the peak plasma concentration of 2.1 +/- 0.6 micrograms/ml (1.5 x 10(-5) M) was reached within 30 to 120 min.,Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),[μg] / [ml],2.1,20028,DB00999,Hydrochlorothiazide
,7094977,peak level,The peak level of oxipurinol of 5.8 +/- 1.5 micrograms/ml (3.8 x 10(-5) M) was found within 2 to 5 h after intravenous and oral allopurinol.,Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),[μg] / [ml],5.8,20029,DB00999,Hydrochlorothiazide
,7094977,bioavailability,The bioavailability of oral allopurinol computed from plasma data was 90.4 +/- 8.7%.,Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),%,90.4,20030,DB00999,Hydrochlorothiazide
,7094977,total recovery from urine,"The total recovery from urine was 77% (allopurinol 8%, oxipurinol 69%) after oral and 88% after i.v. administration.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),%,77,20031,DB00999,Hydrochlorothiazide
,7094977,total recovery from urine,"The total recovery from urine was 77% (allopurinol 8%, oxipurinol 69%) after oral and 88% after i.v. administration.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),%,8,20032,DB00999,Hydrochlorothiazide
,7094977,total recovery from urine,"The total recovery from urine was 77% (allopurinol 8%, oxipurinol 69%) after oral and 88% after i.v. administration.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),%,69,20033,DB00999,Hydrochlorothiazide
,7094977,total recovery from urine,"The total recovery from urine was 77% (allopurinol 8%, oxipurinol 69%) after oral and 88% after i.v. administration.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),%,88,20034,DB00999,Hydrochlorothiazide
,1551742,t1/2,"For example, the mean t1/2 values ranged from 3.2 to 13.1 h and Vdarea values from 1.53 to 4.19 l/kg.",Large differences in the biological half-life and volume of distribution of hydrochlorothiazide in normal subjects from eleven studies. Correlation with their last blood sampling times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1551742/),h,3.2 to 13.1,41050,DB00999,Hydrochlorothiazide
,1551742,Vdarea,"For example, the mean t1/2 values ranged from 3.2 to 13.1 h and Vdarea values from 1.53 to 4.19 l/kg.",Large differences in the biological half-life and volume of distribution of hydrochlorothiazide in normal subjects from eleven studies. Correlation with their last blood sampling times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1551742/),[l] / [kg],1.53 to 4.19,41051,DB00999,Hydrochlorothiazide
,1551742,t1/2,"Furthermore, a t1/2 of only 2.5 h and a Vdarea of only 0.83 l/kg were cited in a recent textbook.",Large differences in the biological half-life and volume of distribution of hydrochlorothiazide in normal subjects from eleven studies. Correlation with their last blood sampling times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1551742/),h,2.5,41052,DB00999,Hydrochlorothiazide
,1551742,Vdarea,"Furthermore, a t1/2 of only 2.5 h and a Vdarea of only 0.83 l/kg were cited in a recent textbook.",Large differences in the biological half-life and volume of distribution of hydrochlorothiazide in normal subjects from eleven studies. Correlation with their last blood sampling times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1551742/),[l] / [kg],0.83,41053,DB00999,Hydrochlorothiazide
,6884417,AUC,"The main pharmacokinetic parameters of acebutolol did not differ significantly: AUC 4492 +/- 272 micrograms l-1h given alone versus 4118 +/- 354 micrograms l-1h with HCT, half-life (7,69 +/- 0,32 h vs 8,10 +/- 0,72 h) and renal clearance (13,1 +/- 0,5 lh-1 vs 13,8 +/- 0,9 lh-1), respectively.",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),[μg] / [l],4492,42619,DB00999,Hydrochlorothiazide
,6884417,AUC,"The main pharmacokinetic parameters of acebutolol did not differ significantly: AUC 4492 +/- 272 micrograms l-1h given alone versus 4118 +/- 354 micrograms l-1h with HCT, half-life (7,69 +/- 0,32 h vs 8,10 +/- 0,72 h) and renal clearance (13,1 +/- 0,5 lh-1 vs 13,8 +/- 0,9 lh-1), respectively.",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),[μg] / [l],4118,42620,DB00999,Hydrochlorothiazide
,6884417,half-life,"The main pharmacokinetic parameters of acebutolol did not differ significantly: AUC 4492 +/- 272 micrograms l-1h given alone versus 4118 +/- 354 micrograms l-1h with HCT, half-life (7,69 +/- 0,32 h vs 8,10 +/- 0,72 h) and renal clearance (13,1 +/- 0,5 lh-1 vs 13,8 +/- 0,9 lh-1), respectively.",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),h,"7,69",42621,DB00999,Hydrochlorothiazide
,6884417,half-life,"The main pharmacokinetic parameters of acebutolol did not differ significantly: AUC 4492 +/- 272 micrograms l-1h given alone versus 4118 +/- 354 micrograms l-1h with HCT, half-life (7,69 +/- 0,32 h vs 8,10 +/- 0,72 h) and renal clearance (13,1 +/- 0,5 lh-1 vs 13,8 +/- 0,9 lh-1), respectively.",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),h,"8,10",42622,DB00999,Hydrochlorothiazide
,6884417,renal clearance,"The main pharmacokinetic parameters of acebutolol did not differ significantly: AUC 4492 +/- 272 micrograms l-1h given alone versus 4118 +/- 354 micrograms l-1h with HCT, half-life (7,69 +/- 0,32 h vs 8,10 +/- 0,72 h) and renal clearance (13,1 +/- 0,5 lh-1 vs 13,8 +/- 0,9 lh-1), respectively.",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),1/[lh],"13,1",42623,DB00999,Hydrochlorothiazide
,6884417,renal clearance,"The main pharmacokinetic parameters of acebutolol did not differ significantly: AUC 4492 +/- 272 micrograms l-1h given alone versus 4118 +/- 354 micrograms l-1h with HCT, half-life (7,69 +/- 0,32 h vs 8,10 +/- 0,72 h) and renal clearance (13,1 +/- 0,5 lh-1 vs 13,8 +/- 0,9 lh-1), respectively.",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),1/[lh],"13,8",42624,DB00999,Hydrochlorothiazide
,6884417,AUC,"HCT values were not significantly different: AUC 784 +/- 48 micrograms l-1h given alone and 720 +/- 42 micrograms l-1h with acebutolol, t 1/2 (4,79 +/- 0,37 h vs 4,73 +/- 0,43 h).",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),[μg] / [l],784,42625,DB00999,Hydrochlorothiazide
,6884417,AUC,"HCT values were not significantly different: AUC 784 +/- 48 micrograms l-1h given alone and 720 +/- 42 micrograms l-1h with acebutolol, t 1/2 (4,79 +/- 0,37 h vs 4,73 +/- 0,43 h).",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),[μg] / [l],720,42626,DB00999,Hydrochlorothiazide
,6884417,t 1/2,"HCT values were not significantly different: AUC 784 +/- 48 micrograms l-1h given alone and 720 +/- 42 micrograms l-1h with acebutolol, t 1/2 (4,79 +/- 0,37 h vs 4,73 +/- 0,43 h).",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),h,"4,79",42627,DB00999,Hydrochlorothiazide
,6884417,t 1/2,"HCT values were not significantly different: AUC 784 +/- 48 micrograms l-1h given alone and 720 +/- 42 micrograms l-1h with acebutolol, t 1/2 (4,79 +/- 0,37 h vs 4,73 +/- 0,43 h).",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),h,"4,73",42628,DB00999,Hydrochlorothiazide
,6884417,renal clearance,"The renal clearance was slightly higher when HCT was given with acebutolol (26,2 +/- 2,6 vs 20,3 +/- 2,1 lh-1, p less than 0,05).",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),1/[lh],"26,2",42629,DB00999,Hydrochlorothiazide
,6884417,renal clearance,"The renal clearance was slightly higher when HCT was given with acebutolol (26,2 +/- 2,6 vs 20,3 +/- 2,1 lh-1, p less than 0,05).",Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6884417/),1/[lh],"20,3",42630,DB00999,Hydrochlorothiazide
,17110179,linear dynamic,"A linear dynamic range of 100-10,000 ng/mL for both theophylline and etofylline was established.",A simple and rapid HPLC/UV method for the simultaneous quantification of theophylline and etofylline in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17110179/),[ng] / [ml],"100-10,000",46765,DB00999,Hydrochlorothiazide
,27114321,flow rate,The chromatographic separation was achieved on a Hedera ODS-2 column with a gradient elution using 10 mmol·L(-1) of ammonium acetate buffer solution containing 0.5% of formic acid - acetonitrile as mobile phase at a flow rate of 300 μL·min(-1).,Simultaneous quantification of chlorogenic acid and taurocholic acid in human plasma by LC-MS/MS and its application to a pharmacokinetic study after oral administration of Shuanghua Baihe tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27114321/),[μl] / [min],300,46771,DB00999,Hydrochlorothiazide
,27114321,maximum plasma concentration (Cmax),"In the single-dose study, the maximum plasma concentration (Cmax), time to reach Cmax (Tmax) and elimination half-life (t1/2) of CGA were (0.763 8 ± 0.542 0) ng·mL(-1), (1.0 ± 0.5) h, and (1.3 ± 0.6) h, respectively.",Simultaneous quantification of chlorogenic acid and taurocholic acid in human plasma by LC-MS/MS and its application to a pharmacokinetic study after oral administration of Shuanghua Baihe tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27114321/),[ng] / [ml],0.763 8,46772,DB00999,Hydrochlorothiazide
,27114321,time to reach Cmax (Tmax),"In the single-dose study, the maximum plasma concentration (Cmax), time to reach Cmax (Tmax) and elimination half-life (t1/2) of CGA were (0.763 8 ± 0.542 0) ng·mL(-1), (1.0 ± 0.5) h, and (1.3 ± 0.6) h, respectively.",Simultaneous quantification of chlorogenic acid and taurocholic acid in human plasma by LC-MS/MS and its application to a pharmacokinetic study after oral administration of Shuanghua Baihe tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27114321/),h,1.0,46773,DB00999,Hydrochlorothiazide
,27114321,elimination half-life (t1/2),"In the single-dose study, the maximum plasma concentration (Cmax), time to reach Cmax (Tmax) and elimination half-life (t1/2) of CGA were (0.763 8 ± 0.542 0) ng·mL(-1), (1.0 ± 0.5) h, and (1.3 ± 0.6) h, respectively.",Simultaneous quantification of chlorogenic acid and taurocholic acid in human plasma by LC-MS/MS and its application to a pharmacokinetic study after oral administration of Shuanghua Baihe tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27114321/),h,1.3,46774,DB00999,Hydrochlorothiazide
,27114321,Cmax,"In the multiple-dose study, the Cmax, Tmax and t1/2 of CGA were (0.663 7 ± 0.583 3) ng·mL(-1), (1.1 ± 0.5) h, and (1.4 ± 0.7) h, respectively.",Simultaneous quantification of chlorogenic acid and taurocholic acid in human plasma by LC-MS/MS and its application to a pharmacokinetic study after oral administration of Shuanghua Baihe tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27114321/),[ng] / [ml],0.663 7,46775,DB00999,Hydrochlorothiazide
,27114321,Tmax,"In the multiple-dose study, the Cmax, Tmax and t1/2 of CGA were (0.663 7 ± 0.583 3) ng·mL(-1), (1.1 ± 0.5) h, and (1.4 ± 0.7) h, respectively.",Simultaneous quantification of chlorogenic acid and taurocholic acid in human plasma by LC-MS/MS and its application to a pharmacokinetic study after oral administration of Shuanghua Baihe tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27114321/),h,1.1,46776,DB00999,Hydrochlorothiazide
,27114321,t1/2,"In the multiple-dose study, the Cmax, Tmax and t1/2 of CGA were (0.663 7 ± 0.583 3) ng·mL(-1), (1.1 ± 0.5) h, and (1.4 ± 0.7) h, respectively.",Simultaneous quantification of chlorogenic acid and taurocholic acid in human plasma by LC-MS/MS and its application to a pharmacokinetic study after oral administration of Shuanghua Baihe tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27114321/),h,1.4,46777,DB00999,Hydrochlorothiazide
,22472448,V/V,"VAL, AML and HCT were resolved using a Gemini C18 column and mobile phase gradient starting from 20 % acetonitrile and 80 % 10 mmol L(-1) ammonium formate (V/V, pH 3.5 ± 0.2, by formic acid) to 70 % acetonitrile and 30 % 10 mmol L(-1) ammonium formate, over 20 minutes, with a flow rate of 1 mL min(-1).","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),,3.5,48975,DB00999,Hydrochlorothiazide
,22472448,flow rate,"VAL, AML and HCT were resolved using a Gemini C18 column and mobile phase gradient starting from 20 % acetonitrile and 80 % 10 mmol L(-1) ammonium formate (V/V, pH 3.5 ± 0.2, by formic acid) to 70 % acetonitrile and 30 % 10 mmol L(-1) ammonium formate, over 20 minutes, with a flow rate of 1 mL min(-1).","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),[ml] / [min],1,48976,DB00999,Hydrochlorothiazide
,22472448,extraction recoveries,"Mean extraction recoveries of three QCs for the triple drug combination were 76.5 (VAL), 72.0 (AML) and 73.0 (HCT) % for human plasma.","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),%,76.5,48977,DB00999,Hydrochlorothiazide
,22472448,extraction recoveries,"Mean extraction recoveries of three QCs for the triple drug combination were 76.5 (VAL), 72.0 (AML) and 73.0 (HCT) % for human plasma.","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),%,72.0,48978,DB00999,Hydrochlorothiazide
,22472448,extraction recoveries,"Mean extraction recoveries of three QCs for the triple drug combination were 76.5 (VAL), 72.0 (AML) and 73.0 (HCT) % for human plasma.","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),%,73.0,48979,DB00999,Hydrochlorothiazide
,3034318,Elimination half-lives,Elimination half-lives of total captopril after acute (7.8 +/- 2.3 h) or chronic (7.0 +/- 0.5 h) captopril dosing were similar to those of HCTZ after acute (6.5 +/- 1.0 h) or chronic (8.0 +/- 2.5 h) HCTZ dosing.,Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034318/),h,7.8,49430,DB00999,Hydrochlorothiazide
,3034318,Elimination half-lives,Elimination half-lives of total captopril after acute (7.8 +/- 2.3 h) or chronic (7.0 +/- 0.5 h) captopril dosing were similar to those of HCTZ after acute (6.5 +/- 1.0 h) or chronic (8.0 +/- 2.5 h) HCTZ dosing.,Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034318/),h,7.0,49431,DB00999,Hydrochlorothiazide
,3034318,Elimination half-lives,Elimination half-lives of total captopril after acute (7.8 +/- 2.3 h) or chronic (7.0 +/- 0.5 h) captopril dosing were similar to those of HCTZ after acute (6.5 +/- 1.0 h) or chronic (8.0 +/- 2.5 h) HCTZ dosing.,Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034318/),h,6.5,49432,DB00999,Hydrochlorothiazide
,3034318,Elimination half-lives,Elimination half-lives of total captopril after acute (7.8 +/- 2.3 h) or chronic (7.0 +/- 0.5 h) captopril dosing were similar to those of HCTZ after acute (6.5 +/- 1.0 h) or chronic (8.0 +/- 2.5 h) HCTZ dosing.,Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034318/),h,8.0,49433,DB00999,Hydrochlorothiazide
,3034318,Elimination half-life,Elimination half-life of free unchanged captopril was 0.81 +/- 0.09 h after acute and 0.96 +/- 0.03 h after chronic captopril dosing.,Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034318/),h,0.81,49434,DB00999,Hydrochlorothiazide
,3034318,Elimination half-life,Elimination half-life of free unchanged captopril was 0.81 +/- 0.09 h after acute and 0.96 +/- 0.03 h after chronic captopril dosing.,Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034318/),h,0.96,49435,DB00999,Hydrochlorothiazide
,6844739,maximum plasma concentration,"A maximum plasma concentration of 50-285 ng/ml was reached in 1-2 hours, and plasma levels declined very rapidly with a half life of about 2-4 hours during first 12 hours period.","Thiazides III. Evidence of dose proportionality of hydrochlorothiazide 25, 50 and 100 mg tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6844739/),[ng] / [ml],50-285,53429,DB00999,Hydrochlorothiazide
,6844739,half life,"A maximum plasma concentration of 50-285 ng/ml was reached in 1-2 hours, and plasma levels declined very rapidly with a half life of about 2-4 hours during first 12 hours period.","Thiazides III. Evidence of dose proportionality of hydrochlorothiazide 25, 50 and 100 mg tablets. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6844739/),h,2-4,53430,DB00999,Hydrochlorothiazide
,576856,Maximal plasma levels,"Maximal plasma levels were significantly (p less than 0.05) higher after Dichlotride than Esidrex, 512 +- 189 and 376 +- 70ng/ml, respectively.",Bioavailability of two hydrochlorothiazide preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/576856/),[ng] / [ml],512,54031,DB00999,Hydrochlorothiazide
,576856,Maximal plasma levels,"Maximal plasma levels were significantly (p less than 0.05) higher after Dichlotride than Esidrex, 512 +- 189 and 376 +- 70ng/ml, respectively.",Bioavailability of two hydrochlorothiazide preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/576856/),[ng] / [ml],376,54032,DB00999,Hydrochlorothiazide
,7082779,bioavailability,"Experiments have been carried out in dogs and man to determine the effect of hydrochlorothiazide (HCT) on the pharmacokinetics of propranolol and to evaluate the bioavailability of two dosage forms containing both propranolol and HCT (40/25 and 80/25 mg, respectively).",Biopharmaceutical characteristics of a new propranolol/hydrochlorothiazide tablet combination. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082779/),mg,40,59942,DB00999,Hydrochlorothiazide
,7082779,bioavailability,"Experiments have been carried out in dogs and man to determine the effect of hydrochlorothiazide (HCT) on the pharmacokinetics of propranolol and to evaluate the bioavailability of two dosage forms containing both propranolol and HCT (40/25 and 80/25 mg, respectively).",Biopharmaceutical characteristics of a new propranolol/hydrochlorothiazide tablet combination. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082779/),mg,80,59943,DB00999,Hydrochlorothiazide
,9010710,area under the plasma concentration-time curve,"For the area under the plasma concentration-time curve calculated from time 0 to a concentration greater than zero, AUC(O-t), the study showed a mean value of moexipril 437 ng.",Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010710/),ng,437,60447,DB00999,Hydrochlorothiazide
,9010710,Cmax,The Cmax of moexipril and the metabolite (data of the metabolite in parenthesis) were 245.4 (70.8) ng.ml-1 after administration of moexipril alone and 241.0 (69.2) ng.ml-1 after coadministration of hydrochlorothiazide.,Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010710/),[ng] / [ml],245.4,60448,DB00999,Hydrochlorothiazide
,9010710,Cmax,The Cmax of moexipril and the metabolite (data of the metabolite in parenthesis) were 245.4 (70.8) ng.ml-1 after administration of moexipril alone and 241.0 (69.2) ng.ml-1 after coadministration of hydrochlorothiazide.,Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010710/),[ng] / [ml],241.0,60449,DB00999,Hydrochlorothiazide
,9010710,total renal excretion (TUE),The mean total renal excretion (TUE) of hydrochlorothiazide was 15.2 mg when administered alone and 15.1 mg when given together with moexipril.,Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010710/),mg,15.2,60450,DB00999,Hydrochlorothiazide
,9010710,total renal excretion (TUE),The mean total renal excretion (TUE) of hydrochlorothiazide was 15.2 mg when administered alone and 15.1 mg when given together with moexipril.,Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010710/),mg,15.1,60451,DB00999,Hydrochlorothiazide
,9010710,TUE-,The corresponding mean TUE-values for moexiprilat were 334 (1200) and 453 (1460) micrograms.,Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010710/),μg,334,60452,DB00999,Hydrochlorothiazide
,9010710,TUE-,The corresponding mean TUE-values for moexiprilat were 334 (1200) and 453 (1460) micrograms.,Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010710/),μg,453,60453,DB00999,Hydrochlorothiazide
,6716243,"peak plasma levels, Cmax","Mean peak plasma levels, Cmax (127-135, 270-280, and 437-490 ng/mL from the 25-, 50-, and 100-mg doses, respectively) were dose proportional, as were areas under plasma profiles, AUC0----36.",Bioavailability of hydrochlorothiazide from tablets and suspensions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716243/),[ng] / [ml],127-135,61157,DB00999,Hydrochlorothiazide
,6716243,"peak plasma levels, Cmax","Mean peak plasma levels, Cmax (127-135, 270-280, and 437-490 ng/mL from the 25-, 50-, and 100-mg doses, respectively) were dose proportional, as were areas under plasma profiles, AUC0----36.",Bioavailability of hydrochlorothiazide from tablets and suspensions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716243/),[ng] / [ml],270-280,61158,DB00999,Hydrochlorothiazide
,6716243,"peak plasma levels, Cmax","Mean peak plasma levels, Cmax (127-135, 270-280, and 437-490 ng/mL from the 25-, 50-, and 100-mg doses, respectively) were dose proportional, as were areas under plasma profiles, AUC0----36.",Bioavailability of hydrochlorothiazide from tablets and suspensions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716243/),[ng] / [ml],437-490,61159,DB00999,Hydrochlorothiazide
,6716243,percentage recovery,"Mean percentage recovery of unchanged hydrochlorothiazide in 48-h urine samples accounted for 50-59, 54-55, 60-63, and 54-57% of the 25-, 50-, 100-, and 200-mg doses, respectively.",Bioavailability of hydrochlorothiazide from tablets and suspensions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716243/),%,50-59,61160,DB00999,Hydrochlorothiazide
,6716243,percentage recovery,"Mean percentage recovery of unchanged hydrochlorothiazide in 48-h urine samples accounted for 50-59, 54-55, 60-63, and 54-57% of the 25-, 50-, 100-, and 200-mg doses, respectively.",Bioavailability of hydrochlorothiazide from tablets and suspensions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716243/),%,54-55,61161,DB00999,Hydrochlorothiazide
,6716243,percentage recovery,"Mean percentage recovery of unchanged hydrochlorothiazide in 48-h urine samples accounted for 50-59, 54-55, 60-63, and 54-57% of the 25-, 50-, 100-, and 200-mg doses, respectively.",Bioavailability of hydrochlorothiazide from tablets and suspensions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716243/),%,60-63,61162,DB00999,Hydrochlorothiazide
,6716243,percentage recovery,"Mean percentage recovery of unchanged hydrochlorothiazide in 48-h urine samples accounted for 50-59, 54-55, 60-63, and 54-57% of the 25-, 50-, 100-, and 200-mg doses, respectively.",Bioavailability of hydrochlorothiazide from tablets and suspensions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716243/),%,54-57,61163,DB00999,Hydrochlorothiazide
,3752167,renal o,No change in renal oxipurinol clearance (21.1 +/- 5.9 vs. 20.4 +/- 8.7 ml/min) or serum oxipurinol half-life (23.7 +/- 4.2 vs. 23.4 +/- 4.4 hours) was noted with the addition of thiazides.,Evaluation of a thiazide-allopurinol drug interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752167/),[ml] / [min],21.1,67171,DB00999,Hydrochlorothiazide
,3752167,renal o,No change in renal oxipurinol clearance (21.1 +/- 5.9 vs. 20.4 +/- 8.7 ml/min) or serum oxipurinol half-life (23.7 +/- 4.2 vs. 23.4 +/- 4.4 hours) was noted with the addition of thiazides.,Evaluation of a thiazide-allopurinol drug interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752167/),[ml] / [min],20.4,67172,DB00999,Hydrochlorothiazide
,3752167,clearance,No change in renal oxipurinol clearance (21.1 +/- 5.9 vs. 20.4 +/- 8.7 ml/min) or serum oxipurinol half-life (23.7 +/- 4.2 vs. 23.4 +/- 4.4 hours) was noted with the addition of thiazides.,Evaluation of a thiazide-allopurinol drug interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752167/),[ml] / [min],21.1,67173,DB00999,Hydrochlorothiazide
,3752167,clearance,No change in renal oxipurinol clearance (21.1 +/- 5.9 vs. 20.4 +/- 8.7 ml/min) or serum oxipurinol half-life (23.7 +/- 4.2 vs. 23.4 +/- 4.4 hours) was noted with the addition of thiazides.,Evaluation of a thiazide-allopurinol drug interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752167/),[ml] / [min],20.4,67174,DB00999,Hydrochlorothiazide
,3752167,half-life,No change in renal oxipurinol clearance (21.1 +/- 5.9 vs. 20.4 +/- 8.7 ml/min) or serum oxipurinol half-life (23.7 +/- 4.2 vs. 23.4 +/- 4.4 hours) was noted with the addition of thiazides.,Evaluation of a thiazide-allopurinol drug interaction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752167/),h,23.7,67175,DB00999,Hydrochlorothiazide
,3752167,half-life,No change in renal oxipurinol clearance (21.1 +/- 5.9 vs. 20.4 +/- 8.7 ml/min) or serum oxipurinol half-life (23.7 +/- 4.2 vs. 23.4 +/- 4.4 hours) was noted with the addition of thiazides.,Evaluation of a thiazide-allopurinol drug interaction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752167/),h,23.4,67176,DB00999,Hydrochlorothiazide
,24974472,F(o-t),The F(o-t) and F(0-infinity) were (139.4 +/- 65.2)% and (137.5 +/- 61.2)% for valsartan of test preparations.,[Troubleshooting of bioinequivalence of compound valsartan tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24974472/),%,139.4,72238,DB00999,Hydrochlorothiazide
,24974472,F(0-infinity),The F(o-t) and F(0-infinity) were (139.4 +/- 65.2)% and (137.5 +/- 61.2)% for valsartan of test preparations.,[Troubleshooting of bioinequivalence of compound valsartan tablets]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24974472/),%,137.5,72239,DB00999,Hydrochlorothiazide
,10510149,Cmax,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[ng] / [ml],387,77454,DB00999,Hydrochlorothiazide
,10510149,Cmax,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[ng] / [ml],324,77455,DB00999,Hydrochlorothiazide
,10510149,tmax,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),h,3.5,77456,DB00999,Hydrochlorothiazide
,10510149,tmax,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),h,3.0,77457,DB00999,Hydrochlorothiazide
,10510149,AUC,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[h·ng] / [ml],3510,77458,DB00999,Hydrochlorothiazide
,10510149,AUC,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[h·ng] / [ml],2701,77459,DB00999,Hydrochlorothiazide
,10510149,CUE,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),%,5.08,77460,DB00999,Hydrochlorothiazide
,10510149,CUE,Fosinoprilat pharmacokinetic parameters on day 1 in renally impaired vs normal patients: Cmax=387+/-0.19 vs 324+/-0.25 ng ml-1 (P=0.07); tmax=3.5 vs 3.0 h (P=0.58); AUC=3510+/-0.29 vs 2701+/-0.35 ng ml-1 h (P=0. 072); CUE=5.08+/-2.70 vs 7.40+/-2.56% (P=0.009).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),%,7.40,77461,DB00999,Hydrochlorothiazide
,10510149,Cmax,Fosinoprilat parameters on day 5: Cmax=517+/-0.40 vs 357+/-0.19 ng ml-1 (P=0. 007); tmax=3.0 vs 3.0 h (P >0.99); AUC=4098+/-0.43 vs 2872+/-0.30 ng ml-1 h (P=0.027); CUE=6.81+/-3.53 vs 8.10+/-2.80% (P=0.068).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[ng] / [ml],517,77462,DB00999,Hydrochlorothiazide
,10510149,Cmax,Fosinoprilat parameters on day 5: Cmax=517+/-0.40 vs 357+/-0.19 ng ml-1 (P=0. 007); tmax=3.0 vs 3.0 h (P >0.99); AUC=4098+/-0.43 vs 2872+/-0.30 ng ml-1 h (P=0.027); CUE=6.81+/-3.53 vs 8.10+/-2.80% (P=0.068).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[ng] / [ml],357,77463,DB00999,Hydrochlorothiazide
,10510149,tmax,Fosinoprilat parameters on day 5: Cmax=517+/-0.40 vs 357+/-0.19 ng ml-1 (P=0. 007); tmax=3.0 vs 3.0 h (P >0.99); AUC=4098+/-0.43 vs 2872+/-0.30 ng ml-1 h (P=0.027); CUE=6.81+/-3.53 vs 8.10+/-2.80% (P=0.068).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),h,3.0,77464,DB00999,Hydrochlorothiazide
,10510149,AUC,Fosinoprilat parameters on day 5: Cmax=517+/-0.40 vs 357+/-0.19 ng ml-1 (P=0. 007); tmax=3.0 vs 3.0 h (P >0.99); AUC=4098+/-0.43 vs 2872+/-0.30 ng ml-1 h (P=0.027); CUE=6.81+/-3.53 vs 8.10+/-2.80% (P=0.068).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[h·ng] / [ml],4098,77465,DB00999,Hydrochlorothiazide
,10510149,AUC,Fosinoprilat parameters on day 5: Cmax=517+/-0.40 vs 357+/-0.19 ng ml-1 (P=0. 007); tmax=3.0 vs 3.0 h (P >0.99); AUC=4098+/-0.43 vs 2872+/-0.30 ng ml-1 h (P=0.027); CUE=6.81+/-3.53 vs 8.10+/-2.80% (P=0.068).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),[h·ng] / [ml],2872,77466,DB00999,Hydrochlorothiazide
,10510149,CUE,Fosinoprilat parameters on day 5: Cmax=517+/-0.40 vs 357+/-0.19 ng ml-1 (P=0. 007); tmax=3.0 vs 3.0 h (P >0.99); AUC=4098+/-0.43 vs 2872+/-0.30 ng ml-1 h (P=0.027); CUE=6.81+/-3.53 vs 8.10+/-2.80% (P=0.068).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),%,6.81,77467,DB00999,Hydrochlorothiazide
,10510149,CUE,Fosinoprilat parameters on day 5: Cmax=517+/-0.40 vs 357+/-0.19 ng ml-1 (P=0. 007); tmax=3.0 vs 3.0 h (P >0.99); AUC=4098+/-0.43 vs 2872+/-0.30 ng ml-1 h (P=0.027); CUE=6.81+/-3.53 vs 8.10+/-2.80% (P=0.068).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),%,8.10,77468,DB00999,Hydrochlorothiazide
,10510149,AI,AI=1. 17+/-0.33 vs 1.06+/-0.23 (P=0.29).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),,1. 17,77469,DB00999,Hydrochlorothiazide
,10510149,AI,AI=1. 17+/-0.33 vs 1.06+/-0.23 (P=0.29).,Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510149/),,1.06,77470,DB00999,Hydrochlorothiazide
,4032271,percentage recovery,There were no significant differences for drug alone versus drug with MgO in the mean percentage recovery (60 versus 62%) and the cumulative amount excreted unchanged in urine over 24 h (2408 versus 2463 micrograms).,Effects of magnesium oxide on trichlormethiazide bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032271/),%,60,77541,DB00999,Hydrochlorothiazide
,4032271,percentage recovery,There were no significant differences for drug alone versus drug with MgO in the mean percentage recovery (60 versus 62%) and the cumulative amount excreted unchanged in urine over 24 h (2408 versus 2463 micrograms).,Effects of magnesium oxide on trichlormethiazide bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032271/),%,62,77542,DB00999,Hydrochlorothiazide
,4032271,cumulative amount excreted unchanged,There were no significant differences for drug alone versus drug with MgO in the mean percentage recovery (60 versus 62%) and the cumulative amount excreted unchanged in urine over 24 h (2408 versus 2463 micrograms).,Effects of magnesium oxide on trichlormethiazide bioavailability. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032271/),μg,2408,77543,DB00999,Hydrochlorothiazide
,4032271,cumulative amount excreted unchanged,There were no significant differences for drug alone versus drug with MgO in the mean percentage recovery (60 versus 62%) and the cumulative amount excreted unchanged in urine over 24 h (2408 versus 2463 micrograms).,Effects of magnesium oxide on trichlormethiazide bioavailability. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032271/),μg,2463,77544,DB00999,Hydrochlorothiazide
,4032271,solubility,The solubility of 1 increased remarkably by changing from pH 1.2 to 8.0 (141 to 1365 micrograms/mL).,Effects of magnesium oxide on trichlormethiazide bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032271/),[μg] / [ml],141 to 1365,77545,DB00999,Hydrochlorothiazide
,15739415,recovery,The recovery of metronidazole from rabbits serum and cerebrospinal fluid are 97.1% +/- 1.5% and 97.4% +/- 1.6% respectively.,[Determination of metronidazole in serum and cerebrospinal fluid with reversed-phase high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739415/),%,97.1,77885,DB00999,Hydrochlorothiazide
,15739415,recovery,The recovery of metronidazole from rabbits serum and cerebrospinal fluid are 97.1% +/- 1.5% and 97.4% +/- 1.6% respectively.,[Determination of metronidazole in serum and cerebrospinal fluid with reversed-phase high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739415/),%,97.4,77886,DB00999,Hydrochlorothiazide
,15739415,minimum detectable quantity,The minimum detectable quantity is 80ng/mL in sample (S/N = 3).,[Determination of metronidazole in serum and cerebrospinal fluid with reversed-phase high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739415/),[ng] / [ml],80,77887,DB00999,Hydrochlorothiazide
,15739415,S/N,The minimum detectable quantity is 80ng/mL in sample (S/N = 3).,[Determination of metronidazole in serum and cerebrospinal fluid with reversed-phase high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739415/),,3,77888,DB00999,Hydrochlorothiazide
,7311392,Bioavailability,"Bioavailability of Hct showed considerable intra- and interindividual variation (32--87% and 42--77% respectively), but phenytoin did not influence the disposition parameters of the diuretic.",Disposition of hydrochlorothiazide (Hct) during phenytoin (Ph) treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7311392/),,32,85619,DB00999,Hydrochlorothiazide
,7311392,Bioavailability,"Bioavailability of Hct showed considerable intra- and interindividual variation (32--87% and 42--77% respectively), but phenytoin did not influence the disposition parameters of the diuretic.",Disposition of hydrochlorothiazide (Hct) during phenytoin (Ph) treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7311392/),,42,85620,DB00999,Hydrochlorothiazide
,1867656,Relative bioavailability,"Relative bioavailability of the FR and SR formulations were 82 and 41%, respectively, compared to the commercial tablet.",In vitro/in vivo evaluation of hydrochlorothiazide in experimental hydrochlorothiazide/triamterene combination tablets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867656/),%,82,86070,DB00999,Hydrochlorothiazide
,1867656,Relative bioavailability,"Relative bioavailability of the FR and SR formulations were 82 and 41%, respectively, compared to the commercial tablet.",In vitro/in vivo evaluation of hydrochlorothiazide in experimental hydrochlorothiazide/triamterene combination tablets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867656/),%,41,86071,DB00999,Hydrochlorothiazide
,20382272,AUC((0)(-)(t)),"A significant improvement in bioavailability was observed with the transdermal patches over oral tablets as observed by the mean AUC((0)(-)(t)) values 4004.37+/-180.98 and 1824.30+/-17.43ngh/mL respectively for CRV and HCTZ as compared to 753.46+/-53.34 and 392.89+/-34.23ngh/mL respectively, with the oral tablets.","Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382272/),[ngh] / [ml],4004.37,89017,DB00999,Hydrochlorothiazide
,20382272,AUC((0)(-)(t)),"A significant improvement in bioavailability was observed with the transdermal patches over oral tablets as observed by the mean AUC((0)(-)(t)) values 4004.37+/-180.98 and 1824.30+/-17.43ngh/mL respectively for CRV and HCTZ as compared to 753.46+/-53.34 and 392.89+/-34.23ngh/mL respectively, with the oral tablets.","Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382272/),[ngh] / [ml],1824.30,89018,DB00999,Hydrochlorothiazide
,20382272,AUC((0)(-)(t)),"A significant improvement in bioavailability was observed with the transdermal patches over oral tablets as observed by the mean AUC((0)(-)(t)) values 4004.37+/-180.98 and 1824.30+/-17.43ngh/mL respectively for CRV and HCTZ as compared to 753.46+/-53.34 and 392.89+/-34.23ngh/mL respectively, with the oral tablets.","Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382272/),[ngh] / [ml],753.46,89019,DB00999,Hydrochlorothiazide
,20382272,AUC((0)(-)(t)),"A significant improvement in bioavailability was observed with the transdermal patches over oral tablets as observed by the mean AUC((0)(-)(t)) values 4004.37+/-180.98 and 1824.30+/-17.43ngh/mL respectively for CRV and HCTZ as compared to 753.46+/-53.34 and 392.89+/-34.23ngh/mL respectively, with the oral tablets.","Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382272/),[ngh] / [ml],392.89,89020,DB00999,Hydrochlorothiazide
,24123104,Non-renal clearance,"Non-renal clearance was estimated to be 2.44 l/h, CLR was 18.3 l/h and T1/2,α was 1.6 h and T1/2,β was 14.8 h for a typical individual with normal renal function (CLCR = 120 ml/min).",Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123104/),[l] / [h],2.44,93540,DB00999,Hydrochlorothiazide
,24123104,CLR,"Non-renal clearance was estimated to be 2.44 l/h, CLR was 18.3 l/h and T1/2,α was 1.6 h and T1/2,β was 14.8 h for a typical individual with normal renal function (CLCR = 120 ml/min).",Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123104/),[l] / [h],18.3,93541,DB00999,Hydrochlorothiazide
,24123104,"T1/2,α","Non-renal clearance was estimated to be 2.44 l/h, CLR was 18.3 l/h and T1/2,α was 1.6 h and T1/2,β was 14.8 h for a typical individual with normal renal function (CLCR = 120 ml/min).",Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123104/),h,1.6,93542,DB00999,Hydrochlorothiazide
,24123104,"T1/2,β","Non-renal clearance was estimated to be 2.44 l/h, CLR was 18.3 l/h and T1/2,α was 1.6 h and T1/2,β was 14.8 h for a typical individual with normal renal function (CLCR = 120 ml/min).",Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123104/),h,14.8,93543,DB00999,Hydrochlorothiazide
,24123104,CLR,"However, CLR was reduced to 10.5, 5.47 and 2.70 l/h in mild (CLCR = 80 ml/min), moderate (CLCR = 50 ml/min) and severe (CLCR = 30 ml/min) renal impairment, respectively.",Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123104/),[l] / [h],10.5,93544,DB00999,Hydrochlorothiazide
,24123104,CLR,"However, CLR was reduced to 10.5, 5.47 and 2.70 l/h in mild (CLCR = 80 ml/min), moderate (CLCR = 50 ml/min) and severe (CLCR = 30 ml/min) renal impairment, respectively.",Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123104/),[l] / [h],5.47,93545,DB00999,Hydrochlorothiazide
,24123104,CLR,"However, CLR was reduced to 10.5, 5.47 and 2.70 l/h in mild (CLCR = 80 ml/min), moderate (CLCR = 50 ml/min) and severe (CLCR = 30 ml/min) renal impairment, respectively.",Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123104/),[l] / [h],2.70,93546,DB00999,Hydrochlorothiazide
,9627074,QT intervals,"Although the potency of QND for QT prolongation was not affected by hypokalaemia, the QT intervals before drug administration were significantly prolonged in hypokalaemic rats (65.90 +/- 1.40 vs 56.60 +/- 0.748 msec, mean +/- SEM, p < 0.0001).",Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9627074/),ms,65.90,104276,DB00999,Hydrochlorothiazide
,9627074,QT intervals,"Although the potency of QND for QT prolongation was not affected by hypokalaemia, the QT intervals before drug administration were significantly prolonged in hypokalaemic rats (65.90 +/- 1.40 vs 56.60 +/- 0.748 msec, mean +/- SEM, p < 0.0001).",Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9627074/),ms,56.60,104277,DB00999,Hydrochlorothiazide
,6084123,relative bioavailability (Fr),The relative bioavailability (Fr) of the combination tablet compared with guanabenz alone was 96%; thus the two formulations were bioequivalent with respect to guanabenz.,Effects of guanabenz on gastrointestinal absorption of hydrochlorothiazide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6084123/),%,96,105395,DB00999,Hydrochlorothiazide
,6084123,Fr,"A significant increase in the extent, but not the rate, of absorption of hydrochlorothiazide was observed for the combination tablet (mean Fr, 120%), which is not considered clinically significant.",Effects of guanabenz on gastrointestinal absorption of hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6084123/),%,120,105396,DB00999,Hydrochlorothiazide
,4028626,Renal clearance,"Renal clearance of T was 314.5 +/- 121.6 ml/min, exceeding that of the metabolite, which was 206.1 +/- 93.6 ml/min.",Oral triamterene disposition. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028626/),[ml] / [min],314.5,106478,DB00999,Hydrochlorothiazide
,4028626,Renal clearance,"Renal clearance of T was 314.5 +/- 121.6 ml/min, exceeding that of the metabolite, which was 206.1 +/- 93.6 ml/min.",Oral triamterene disposition. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028626/),[ml] / [min],206.1,106479,DB00999,Hydrochlorothiazide
,22007522,fluctuation index (FI),"Administered with the test medication, lisinopril has an fluctuation index (FI) value of 2.29 and reaches a relative steady concentration.",Pharmacokinetics of the combined preparation of lisinopril and hydrochlorothiazide on Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007522/),,2.29,108150,DB00999,Hydrochlorothiazide
,22007522,FI,But hydrochlorothiazide has an FI value of 4.09 with relatively large fluctuating concentrations.,Pharmacokinetics of the combined preparation of lisinopril and hydrochlorothiazide on Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007522/),,4.09,108151,DB00999,Hydrochlorothiazide
,8061850,terminal half-life,"After intravenous infusion, the disposition of spirapril is monophasic with a terminal half-life of 20-50 minutes.",Spirapril: pharmacokinetic properties and drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),min,20-50,108588,DB00999,Hydrochlorothiazide
,8061850,Plasma clearance,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],56,108589,DB00999,Hydrochlorothiazide
,8061850,renal clearance,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],11,108590,DB00999,Hydrochlorothiazide
,8061850,volume of distribution,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),l,28,108591,DB00999,Hydrochlorothiazide
,8061850,half-lives,"After intravenous infusion of spiraprilat, the disposition was biphasic with half-lives of 2 hours and 35 hours, respectively.",Spirapril: pharmacokinetic properties and drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),h,2,108592,DB00999,Hydrochlorothiazide
,8061850,half-lives,"After intravenous infusion of spiraprilat, the disposition was biphasic with half-lives of 2 hours and 35 hours, respectively.",Spirapril: pharmacokinetic properties and drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),h,35,108593,DB00999,Hydrochlorothiazide
,8061850,Plasma clearance,"Plasma clearance of spiraprilat was 10 l/h, of which 7.6 l/h was cleared by the kidneys.",Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],10,108594,DB00999,Hydrochlorothiazide
,8061850,Plasma clearance,"Plasma clearance of spiraprilat was 10 l/h, of which 7.6 l/h was cleared by the kidneys.",Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],7.6,108595,DB00999,Hydrochlorothiazide
,8061850,volume of distribution,The volume of distribution was 43 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),l,43,108596,DB00999,Hydrochlorothiazide
,8061850,bioavailability,The bioavailability of orally administered spirapril was 50% whereas the bioavailability of orally administered spiraprilat was virtually zero.,Spirapril: pharmacokinetic properties and drug interactions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),%,50,108597,DB00999,Hydrochlorothiazide
,20079994,flow rate,"Sample preparation by liquid-liquid extraction with diethyl ether-dichloromethane (60:40, v/v) was followed by chromatography on a Venusil MP-C18 column using methanol-ammonium acetate (10mM)-formic acid (pH 3.4) (50:50:0.05, v/v/v) at a flow rate of 0.8mL/min.",Simultaneous quantitation of hydrochlorothiazide and metoprolol in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079994/),[ml] / [min],0.8,108680,DB00999,Hydrochlorothiazide
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,3.0,108999,DB00999,Hydrochlorothiazide
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,1.2,109000,DB00999,Hydrochlorothiazide
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,less,109001,DB00999,Hydrochlorothiazide
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,100,109002,DB00999,Hydrochlorothiazide
,11549204,PRA,"PRA increased significantly following I alone (1.5-2.0 ng/ml/h), as well as combined with N (2.5 ng/ ml/h) or H (3.1 ng/ml/h).","Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549204/),[ng] / [h·ml],1.5-2.0,109392,DB00999,Hydrochlorothiazide
,11549204,PRA,"PRA increased significantly following I alone (1.5-2.0 ng/ml/h), as well as combined with N (2.5 ng/ ml/h) or H (3.1 ng/ml/h).","Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549204/),[ng] / [h·ml],2.5,109393,DB00999,Hydrochlorothiazide
,11549204,PRA,"PRA increased significantly following I alone (1.5-2.0 ng/ml/h), as well as combined with N (2.5 ng/ ml/h) or H (3.1 ng/ml/h).","Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549204/),[ng] / [h·ml],3.1,109394,DB00999,Hydrochlorothiazide
,1277708,gastrointestinal absorption,"The gastrointestinal absorption ranged between 60% and 80%, most of it took place in the duodenum and the upper jejunum.","Absorption, metabolism, and excretion of hydrochlorothiazide. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277708/),%,60,111252,DB00999,Hydrochlorothiazide
,1277708,gastrointestinal absorption,"The gastrointestinal absorption ranged between 60% and 80%, most of it took place in the duodenum and the upper jejunum.","Absorption, metabolism, and excretion of hydrochlorothiazide. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277708/),%,80,111253,DB00999,Hydrochlorothiazide
,1277708,half-lives,"His plasma levels of hct (determined with gas-liquid chromatography) declined according to a 2-compartment model, the half-lives of the alpha-and beta-phases being 1.7 and 13.1 hr, respectively.","Absorption, metabolism, and excretion of hydrochlorothiazide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277708/),h,1.7,111254,DB00999,Hydrochlorothiazide
,1277708,half-lives,"His plasma levels of hct (determined with gas-liquid chromatography) declined according to a 2-compartment model, the half-lives of the alpha-and beta-phases being 1.7 and 13.1 hr, respectively.","Absorption, metabolism, and excretion of hydrochlorothiazide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277708/),h,13.1,111255,DB00999,Hydrochlorothiazide
,27017568,flow rate,"All biosamples were processed by liquid-liquid extraction and chromatographed on C18- reversed phase column using mobile phase consisting of ammonium acetate (10mM, pH 4) - acetonitrile (10:90, v/v) at a flow rate of 0.5mL/min.",Analysis of bacopaside I in biomatrices using liquid chromatography-tandem mass spectrometry: Pharmacokinetics and brain distribution in Swiss-albino mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27017568/),[ml] / [min],0.5,119614,DB00999,Hydrochlorothiazide
,1712269,terminal half-life,"In clinical pharmacology studies, cilazapril, after its bioactivation to cilazaprilat, was characterised as a potent, reversible angiotensin converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours, which is consistent with saturable binding to ACE.",Clinical pharmacology of cilazapril. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712269/),h,30 to 50,120675,DB00999,Hydrochlorothiazide
,16541390,flow rate,The mobile phase consisted of 55% acetonitrile in water containing 0.3% v/v formic acid and pumped at a flow rate of 0.15 ml min(-1).,"Development and validation of a liquid chromatographic/electrospray ionization mass spectrometric method for the determination of benazepril, benazeprilat and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16541390/),[ml] / [min],0.15,120959,DB00999,Hydrochlorothiazide
,6873147,half-life of elimination,"The half-life of elimination increased from 6.4 h in subjects with normal renal function to 11.5 h in patients with mild renal impairment (endogenous creatinine clearance between 30 and 90 ml/min), and to 20.7 h in patients with an endogenous creatinine clearance below 30 ml/min.",Pharmacokinetics of hydrochlorothiazide in relation to renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873147/),h,6.4,121144,DB00999,Hydrochlorothiazide
,6873147,half-life of elimination,"The half-life of elimination increased from 6.4 h in subjects with normal renal function to 11.5 h in patients with mild renal impairment (endogenous creatinine clearance between 30 and 90 ml/min), and to 20.7 h in patients with an endogenous creatinine clearance below 30 ml/min.",Pharmacokinetics of hydrochlorothiazide in relation to renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873147/),h,11.5,121145,DB00999,Hydrochlorothiazide
,6873147,half-life of elimination,"The half-life of elimination increased from 6.4 h in subjects with normal renal function to 11.5 h in patients with mild renal impairment (endogenous creatinine clearance between 30 and 90 ml/min), and to 20.7 h in patients with an endogenous creatinine clearance below 30 ml/min.",Pharmacokinetics of hydrochlorothiazide in relation to renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873147/),h,20.7,121146,DB00999,Hydrochlorothiazide
,20642548,C(max),"Mean febuxostat C(max), AUC((0-t)), AUC((0-infinity)), t(1/2,z), CL/F and V(ss)/F values for regimens co-administration/febuxostat alone were 2.9/2.9 microg ml(-1), 9.3/9.1 microg ml(-1) h, 9.6/9.3 microg ml(-1) h, 6.5/6.1 h, 8.8/9.3 l h(-1) and 45/44 l, respectively.","Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642548/),[μg] / [ml],2.9,121379,DB00999,Hydrochlorothiazide
,20642548,AUC((0-t)),"Mean febuxostat C(max), AUC((0-t)), AUC((0-infinity)), t(1/2,z), CL/F and V(ss)/F values for regimens co-administration/febuxostat alone were 2.9/2.9 microg ml(-1), 9.3/9.1 microg ml(-1) h, 9.6/9.3 microg ml(-1) h, 6.5/6.1 h, 8.8/9.3 l h(-1) and 45/44 l, respectively.","Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642548/),[h·μg] / [ml],9.3,121380,DB00999,Hydrochlorothiazide
,20642548,AUC((0-infinity)),"Mean febuxostat C(max), AUC((0-t)), AUC((0-infinity)), t(1/2,z), CL/F and V(ss)/F values for regimens co-administration/febuxostat alone were 2.9/2.9 microg ml(-1), 9.3/9.1 microg ml(-1) h, 9.6/9.3 microg ml(-1) h, 6.5/6.1 h, 8.8/9.3 l h(-1) and 45/44 l, respectively.","Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642548/),[h·μg] / [ml],9.3,121381,DB00999,Hydrochlorothiazide
,20642548,"t(1/2,z)","Mean febuxostat C(max), AUC((0-t)), AUC((0-infinity)), t(1/2,z), CL/F and V(ss)/F values for regimens co-administration/febuxostat alone were 2.9/2.9 microg ml(-1), 9.3/9.1 microg ml(-1) h, 9.6/9.3 microg ml(-1) h, 6.5/6.1 h, 8.8/9.3 l h(-1) and 45/44 l, respectively.","Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642548/),[h·μg] / [ml],9.3,121382,DB00999,Hydrochlorothiazide
,20642548,CL/F,"Mean febuxostat C(max), AUC((0-t)), AUC((0-infinity)), t(1/2,z), CL/F and V(ss)/F values for regimens co-administration/febuxostat alone were 2.9/2.9 microg ml(-1), 9.3/9.1 microg ml(-1) h, 9.6/9.3 microg ml(-1) h, 6.5/6.1 h, 8.8/9.3 l h(-1) and 45/44 l, respectively.","Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642548/),[h·μg] / [ml],9.3,121383,DB00999,Hydrochlorothiazide
,20642548,V(ss)/F,"Mean febuxostat C(max), AUC((0-t)), AUC((0-infinity)), t(1/2,z), CL/F and V(ss)/F values for regimens co-administration/febuxostat alone were 2.9/2.9 microg ml(-1), 9.3/9.1 microg ml(-1) h, 9.6/9.3 microg ml(-1) h, 6.5/6.1 h, 8.8/9.3 l h(-1) and 45/44 l, respectively.","Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642548/),l,45,121384,DB00999,Hydrochlorothiazide
,20642548,C,"Serum uric acid C(mean,24h), C(mean,48h) and CL(R) for both regimens co-administration/febuxostat alone were 216/203 micromol l(-1), 218/202 micromol l(-1) and 9.1/10.1 ml min(-1), respectively.","Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642548/),[μM] / [l],216,121385,DB00999,Hydrochlorothiazide
,20642548,C,"Serum uric acid C(mean,24h), C(mean,48h) and CL(R) for both regimens co-administration/febuxostat alone were 216/203 micromol l(-1), 218/202 micromol l(-1) and 9.1/10.1 ml min(-1), respectively.","Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642548/),[μM] / [l],218/,121386,DB00999,Hydrochlorothiazide
,20642548,CL(R),"Serum uric acid C(mean,24h), C(mean,48h) and CL(R) for both regimens co-administration/febuxostat alone were 216/203 micromol l(-1), 218/202 micromol l(-1) and 9.1/10.1 ml min(-1), respectively.","Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. ",CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642548/),[μM] / [l],202,121387,DB00999,Hydrochlorothiazide
,20642548,CL(R),"Serum uric acid C(mean,24h), C(mean,48h) and CL(R) for both regimens co-administration/febuxostat alone were 216/203 micromol l(-1), 218/202 micromol l(-1) and 9.1/10.1 ml min(-1), respectively.","Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. ",CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642548/),[ml] / [min],9.1,121388,DB00999,Hydrochlorothiazide
>,29897424,extraction recovery,"The mean extraction recovery for analytes and ISs were >(86.0%), consistent across all four QC levels.",Challenges in Simultaneous Determination of Hydrochlorothiazide and Ramipril in Human Plasma: Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897424/),%,86.0,128528,DB00999,Hydrochlorothiazide
,23471702,Cmax,"Test and reference formulations gave a mean Cmax of 5.234±0.914 ng/mL and 4.991±0.563 ng/mL, 108.839±13.601 ng/mL and 114.783±12.315 ng/mL and 97.814±10.779 ng/mL and 93.731±10.018 ng/mL for amlodipine, telmisartan and hydrochlorothiazide respectively.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[ng] / [ml],5.234,129263,DB00999,Hydrochlorothiazide
,23471702,Cmax,"Test and reference formulations gave a mean Cmax of 5.234±0.914 ng/mL and 4.991±0.563 ng/mL, 108.839±13.601 ng/mL and 114.783±12.315 ng/mL and 97.814±10.779 ng/mL and 93.731±10.018 ng/mL for amlodipine, telmisartan and hydrochlorothiazide respectively.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[ng] / [ml],4.991,129264,DB00999,Hydrochlorothiazide
,23471702,Cmax,"Test and reference formulations gave a mean Cmax of 5.234±0.914 ng/mL and 4.991±0.563 ng/mL, 108.839±13.601 ng/mL and 114.783±12.315 ng/mL and 97.814±10.779 ng/mL and 93.731±10.018 ng/mL for amlodipine, telmisartan and hydrochlorothiazide respectively.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[ng] / [ml],108.839,129265,DB00999,Hydrochlorothiazide
,23471702,Cmax,"Test and reference formulations gave a mean Cmax of 5.234±0.914 ng/mL and 4.991±0.563 ng/mL, 108.839±13.601 ng/mL and 114.783±12.315 ng/mL and 97.814±10.779 ng/mL and 93.731±10.018 ng/mL for amlodipine, telmisartan and hydrochlorothiazide respectively.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[ng] / [ml],114.783,129266,DB00999,Hydrochlorothiazide
,23471702,Cmax,"Test and reference formulations gave a mean Cmax of 5.234±0.914 ng/mL and 4.991±0.563 ng/mL, 108.839±13.601 ng/mL and 114.783±12.315 ng/mL and 97.814±10.779 ng/mL and 93.731±10.018 ng/mL for amlodipine, telmisartan and hydrochlorothiazide respectively.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[ng] / [ml],97.814,129267,DB00999,Hydrochlorothiazide
,23471702,Cmax,"Test and reference formulations gave a mean Cmax of 5.234±0.914 ng/mL and 4.991±0.563 ng/mL, 108.839±13.601 ng/mL and 114.783±12.315 ng/mL and 97.814±10.779 ng/mL and 93.731±10.018 ng/mL for amlodipine, telmisartan and hydrochlorothiazide respectively.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[ng] / [ml],93.731,129268,DB00999,Hydrochlorothiazide
,23471702,AUC0-t,"The AUC0-t of amlodipine, telmisartan and hydrochlorothiazide was 161.484 ng.h/mL, 1 917.644 ng.h/mL and 822.847 ng.h/mL for test formulation and 162.108 ng.h/mL, 2 014.764 ng.h/mL and 829.323 ng.h/mL for reference in the fasting state.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[h·ng] / [ml],161.484,129269,DB00999,Hydrochlorothiazide
,23471702,AUC0-t,"The AUC0-t of amlodipine, telmisartan and hydrochlorothiazide was 161.484 ng.h/mL, 1 917.644 ng.h/mL and 822.847 ng.h/mL for test formulation and 162.108 ng.h/mL, 2 014.764 ng.h/mL and 829.323 ng.h/mL for reference in the fasting state.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[h·ng] / [ml],1 917.644,129270,DB00999,Hydrochlorothiazide
,23471702,AUC0-t,"The AUC0-t of amlodipine, telmisartan and hydrochlorothiazide was 161.484 ng.h/mL, 1 917.644 ng.h/mL and 822.847 ng.h/mL for test formulation and 162.108 ng.h/mL, 2 014.764 ng.h/mL and 829.323 ng.h/mL for reference in the fasting state.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[h·ng] / [ml],822.847,129271,DB00999,Hydrochlorothiazide
,23471702,AUC0-t,"The AUC0-t of amlodipine, telmisartan and hydrochlorothiazide was 161.484 ng.h/mL, 1 917.644 ng.h/mL and 822.847 ng.h/mL for test formulation and 162.108 ng.h/mL, 2 014.764 ng.h/mL and 829.323 ng.h/mL for reference in the fasting state.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[h·ng] / [ml],162.108,129272,DB00999,Hydrochlorothiazide
,23471702,AUC0-t,"The AUC0-t of amlodipine, telmisartan and hydrochlorothiazide was 161.484 ng.h/mL, 1 917.644 ng.h/mL and 822.847 ng.h/mL for test formulation and 162.108 ng.h/mL, 2 014.764 ng.h/mL and 829.323 ng.h/mL for reference in the fasting state.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[h·ng] / [ml],2 014.764,129273,DB00999,Hydrochlorothiazide
,23471702,AUC0-t,"The AUC0-t of amlodipine, telmisartan and hydrochlorothiazide was 161.484 ng.h/mL, 1 917.644 ng.h/mL and 822.847 ng.h/mL for test formulation and 162.108 ng.h/mL, 2 014.764 ng.h/mL and 829.323 ng.h/mL for reference in the fasting state.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[h·ng] / [ml],829.323,129274,DB00999,Hydrochlorothiazide
,26041408,oral bioavailability,Dose-proportional systemic exposure to canagliflozin has been observed over a wide dose range (50-1600 mg) with an oral bioavailability of 65 %.,"Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),%,65,135780,DB00999,Hydrochlorothiazide
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,10.6,135781,DB00999,Hydrochlorothiazide
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,13.1,135782,DB00999,Hydrochlorothiazide
,2792171,apparent systemic plasma clearance,"The apparent systemic plasma clearance for both amiloride and hydrochlorothiazide was significantly reduced in the elderly when compared to the young (from 753 to 325 ml.min-1, amiloride; and from 418 to 157 ml.min-1, hydrochlorothiazide).",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),[ml] / [min],753 to 325,138405,DB00999,Hydrochlorothiazide
,2792171,apparent systemic plasma clearance,"The apparent systemic plasma clearance for both amiloride and hydrochlorothiazide was significantly reduced in the elderly when compared to the young (from 753 to 325 ml.min-1, amiloride; and from 418 to 157 ml.min-1, hydrochlorothiazide).",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),[ml] / [min],418 to 157,138406,DB00999,Hydrochlorothiazide
,2792171,plasma concentrations at steady state,The plasma concentrations at steady state for both drugs were greatly increased in the elderly patients (Amiloride: from 7 to 25 ng.,The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),ng,7 to 25,138407,DB00999,Hydrochlorothiazide
,2792171,"Css,max","ml-1, Css,max; from 2 to 8 ng.",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),ng,2 to 8,138408,DB00999,Hydrochlorothiazide
,2792171,Css,"ml-1, Css,min; and from 4 to 14 ng.",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),ng,min,138409,DB00999,Hydrochlorothiazide
,2792171,Css,"ml-1, Css,min; and from 4 to 14 ng.",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),ng,4 to 14,138410,DB00999,Hydrochlorothiazide
,2792171,"Css,max","ml-1, Cav; Hydrochlorothiazide: from 184 to 651 ng.ml-1, Css,max; from 31 to 121 ng.ml-1, Css,min; and from 89 to 273 ng.ml-1, Cav).",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),[ng] / [ml],184 to 651,138411,DB00999,Hydrochlorothiazide
,2792171,"Css,min","ml-1, Cav; Hydrochlorothiazide: from 184 to 651 ng.ml-1, Css,max; from 31 to 121 ng.ml-1, Css,min; and from 89 to 273 ng.ml-1, Cav).",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),[ng] / [ml],31 to 121,138412,DB00999,Hydrochlorothiazide
,2792171,Cav,"ml-1, Cav; Hydrochlorothiazide: from 184 to 651 ng.ml-1, Css,max; from 31 to 121 ng.ml-1, Css,min; and from 89 to 273 ng.ml-1, Cav).",The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792171/),[ng] / [ml],89 to 273,138413,DB00999,Hydrochlorothiazide
,3599650,Fractional chloride delivery,Fractional chloride delivery to early distal tubules was 10.8 +/- 0.4% in control but 6.2 +/- 0.3% in indomethacin rats (P less than 0.001).,Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3599650/),%,10.8,140138,DB00999,Hydrochlorothiazide
,3599650,Fractional chloride delivery,Fractional chloride delivery to early distal tubules was 10.8 +/- 0.4% in control but 6.2 +/- 0.3% in indomethacin rats (P less than 0.001).,Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3599650/),%,6.2,140139,DB00999,Hydrochlorothiazide
,3599650,reabsorption,Calculated loop chloride reabsorption was greater in indomethacin than control rats during hydrochlorothiazide administration (41.0 +/- 1.6% vs. 34.3 +/- 2.3%; P less than 0.05).,Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3599650/),%,41.0,140140,DB00999,Hydrochlorothiazide
,3599650,reabsorption,Calculated loop chloride reabsorption was greater in indomethacin than control rats during hydrochlorothiazide administration (41.0 +/- 1.6% vs. 34.3 +/- 2.3%; P less than 0.05).,Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3599650/),%,34.3,140141,DB00999,Hydrochlorothiazide
,3599650,Fractional chloride delivery,"Fractional chloride delivery to late distal tubules was 7.8 +/- 0.7% in control and 4.6 +/- 0.3% in indomethacin rats (P less than 0.005), but distal tubule chloride reabsorption was not different between groups.",Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3599650/),%,7.8,140142,DB00999,Hydrochlorothiazide
,3599650,Fractional chloride delivery,"Fractional chloride delivery to late distal tubules was 7.8 +/- 0.7% in control and 4.6 +/- 0.3% in indomethacin rats (P less than 0.005), but distal tubule chloride reabsorption was not different between groups.",Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3599650/),%,4.6,140143,DB00999,Hydrochlorothiazide
,29604332,time to reach peak (Tmax),"In addition, there was an increasing trend in time to reach peak (Tmax) of VAL in FDCs, where it was increased by 0.22-0.34 h in mean and 0.40-0.44 h in median, except the combination of VAL/HCT at 160/12.5 mg.",Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29604332/),h,0.22-0.34,141590,DB00999,Hydrochlorothiazide
,29604332,time to reach peak (Tmax),"In addition, there was an increasing trend in time to reach peak (Tmax) of VAL in FDCs, where it was increased by 0.22-0.34 h in mean and 0.40-0.44 h in median, except the combination of VAL/HCT at 160/12.5 mg.",Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29604332/),h,0.40-0.44,141591,DB00999,Hydrochlorothiazide
,1330574,Ki,"The relationships between serum enalaprilat and serum ACE activity were similar after both treatments, both consistent with a value for Ki of enalaprilat of about 0.1 nmol.l-1.",The influence of hydrochlorothiazide on the pharmacokinetics of enalapril in elderly patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330574/),[nM] / [l],0.1,144780,DB00999,Hydrochlorothiazide
,21491473,m,"The ion transitions recorded in multiple reaction monitoring mode were m/z 230.1 → 116.0 for amiloride, m/z 254.1 → 237.1 for internal standard, triamterine in positive mode and m/z 296.1 → 204.9 for hydrochlorothiazide, m/z 299.2 → 205.8 for internal standard, hydrochlorothiazide (13)C,d2 in negative ion mode.","A single, selective and simple validated method for simultaneous estimation of amiloride and hydrochlorothiazide in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491473/),,296.1,145115,DB00999,Hydrochlorothiazide
,21491473,m/z,"The ion transitions recorded in multiple reaction monitoring mode were m/z 230.1 → 116.0 for amiloride, m/z 254.1 → 237.1 for internal standard, triamterine in positive mode and m/z 296.1 → 204.9 for hydrochlorothiazide, m/z 299.2 → 205.8 for internal standard, hydrochlorothiazide (13)C,d2 in negative ion mode.","A single, selective and simple validated method for simultaneous estimation of amiloride and hydrochlorothiazide in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491473/),,299.2,145116,DB00999,Hydrochlorothiazide
,21491473,m/z,"The ion transitions recorded in multiple reaction monitoring mode were m/z 230.1 → 116.0 for amiloride, m/z 254.1 → 237.1 for internal standard, triamterine in positive mode and m/z 296.1 → 204.9 for hydrochlorothiazide, m/z 299.2 → 205.8 for internal standard, hydrochlorothiazide (13)C,d2 in negative ion mode.","A single, selective and simple validated method for simultaneous estimation of amiloride and hydrochlorothiazide in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491473/),,205.8,145117,DB00999,Hydrochlorothiazide
,21491473,recovery,The mean recovery was 41.1 and 81.5% for amiloride and hydrochlorothiazide respectively.,"A single, selective and simple validated method for simultaneous estimation of amiloride and hydrochlorothiazide in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491473/),%,41.1,145118,DB00999,Hydrochlorothiazide
,21491473,recovery,The mean recovery was 41.1 and 81.5% for amiloride and hydrochlorothiazide respectively.,"A single, selective and simple validated method for simultaneous estimation of amiloride and hydrochlorothiazide in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491473/),%,81.5,145119,DB00999,Hydrochlorothiazide
,22784220,Peff,"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),[cm] / [s],0.16-44.16 × 10(-4),154149,DB00999,Hydrochlorothiazide
,22784220,fraction unbound to plasma proteins (fu),"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.01-0.99,154150,DB00999,Hydrochlorothiazide
,22784220,Saliva/plasma concentrations ratios,"Saliva/plasma concentrations ratios ranged 0.11-13.4, in agreement with drug protein binding and permeability.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.11-13.4,154151,DB00999,Hydrochlorothiazide
,658108,urinary recovery,The urinary recovery of hct totalled 55.6 +/- 4.9 mg when the drug was given with food and 47.4 +/- 6.0 when it was taken on an empty stomach.,Gastrointestinal absorption of hydrochlorothiazide enhanced by concomitant intake of food. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/658108/),mg,55.6,155613,DB00999,Hydrochlorothiazide
,658108,urinary recovery,The urinary recovery of hct totalled 55.6 +/- 4.9 mg when the drug was given with food and 47.4 +/- 6.0 when it was taken on an empty stomach.,Gastrointestinal absorption of hydrochlorothiazide enhanced by concomitant intake of food. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/658108/),,47.4,155614,DB00999,Hydrochlorothiazide
,19764575,distributional half-life (t1/2alpha),"30 h of distributional half-life (t1/2alpha), 42.",[Antihypertensive effect and pharmacokinetics of low molecular mass potassium alginate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764575/),h,30,161240,DB00999,Hydrochlorothiazide
,19764575,distributional half-life (t1/2alpha),"30 h of distributional half-life (t1/2alpha), 42.",[Antihypertensive effect and pharmacokinetics of low molecular mass potassium alginate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764575/),,42,161241,DB00999,Hydrochlorothiazide
,19764575,elimination half-life (t1/2beta),"31 h of elimination half-life (t1/2beta), and 36.28 h of terminal phase elimination half-life (t1/2z).",[Antihypertensive effect and pharmacokinetics of low molecular mass potassium alginate]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764575/),h,31,161242,DB00999,Hydrochlorothiazide
,19764575,terminal phase elimination half-life (t1/2z),"31 h of elimination half-life (t1/2beta), and 36.28 h of terminal phase elimination half-life (t1/2z).",[Antihypertensive effect and pharmacokinetics of low molecular mass potassium alginate]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764575/),h,36.28,161243,DB00999,Hydrochlorothiazide
,18838240,flow rate,"The analytes and internal standard, probenecid, were separated on a Venusil XBP-C(8) column using gradient elution with acetonitrile-10 mM ammonium acetate-formic acid at a flow rate of 1.2 mL/min.",Liquid chromatographic-tandem mass spectrometric method for the simultaneous quantitation of telmisartan and hydrochlorothiazide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18838240/),[ml] / [min],1.2,167271,DB00999,Hydrochlorothiazide
,2532460,terminal half-life,"In clinical pharmacology studies cilazapril, after its bioactivation to cilazaprilat, was characterized as a potent, reversible angiotensin-converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours consistent with saturable binding to ACE.",Clinical pharmacology of cilazapril. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2532460/),h,30 to 50,171142,DB00999,Hydrochlorothiazide
,10701815,sodium excretion,After HCTZ sodium excretion increased comparably in both groups (blacks: 122 +/- 42 pre to 265 +/- 49 mEq/24 hours post; whites: 117 +/- 29 pre to 255 beta 39 mEq/24 hrs post).,Racial differences in response to acute dosing with hydrochlorothiazide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701815/),[meq] / [24·h],122,173227,DB00999,Hydrochlorothiazide
,10701815,sodium excretion,After HCTZ sodium excretion increased comparably in both groups (blacks: 122 +/- 42 pre to 265 +/- 49 mEq/24 hours post; whites: 117 +/- 29 pre to 255 beta 39 mEq/24 hrs post).,Racial differences in response to acute dosing with hydrochlorothiazide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701815/),[meq] / [24·h],265,173228,DB00999,Hydrochlorothiazide
,10701815,sodium excretion,After HCTZ sodium excretion increased comparably in both groups (blacks: 122 +/- 42 pre to 265 +/- 49 mEq/24 hours post; whites: 117 +/- 29 pre to 255 beta 39 mEq/24 hrs post).,Racial differences in response to acute dosing with hydrochlorothiazide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701815/),,117,173229,DB00999,Hydrochlorothiazide
,10701815,sodium excretion,After HCTZ sodium excretion increased comparably in both groups (blacks: 122 +/- 42 pre to 265 +/- 49 mEq/24 hours post; whites: 117 +/- 29 pre to 255 beta 39 mEq/24 hrs post).,Racial differences in response to acute dosing with hydrochlorothiazide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701815/),[meq] / [24·h],255,173230,DB00999,Hydrochlorothiazide
,12504198,flow-rate,Good chromatographic separation was achieved using a Supelcocil C(18) (5 micrometer 15 cmx4.6 mm) column and a mobile phase consisting of 10 mM potassium dihydrogen phosphate:methanol:acetonitrile (5:80:15 v/v/v) (pH:2.5) while at a flow-rate of 1.0 ml min(-1).,Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504198/),[ml] / [min],1.0,177100,DB00999,Hydrochlorothiazide
,10379636,Cin,"Cin was significantly (P < 0.01) lower in the healthy elderly subjects [104 (12) vs 120 (14) ml x min(-2) x 1.73 m(-2) in the young], but remained within the normal range (> 90 ml x min(-2) x 1.73 m(-2)).",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[1.73·ml] / [(m)^2·(min)^2],104,181416,DB00999,Hydrochlorothiazide
,10379636,Cin,"Cin was significantly (P < 0.01) lower in the healthy elderly subjects [104 (12) vs 120 (14) ml x min(-2) x 1.73 m(-2) in the young], but remained within the normal range (> 90 ml x min(-2) x 1.73 m(-2)).",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[1.73·ml] / [(m)^2·(min)^2],120,181417,DB00999,Hydrochlorothiazide
>,10379636,Cin,"Cin was significantly (P < 0.01) lower in the healthy elderly subjects [104 (12) vs 120 (14) ml x min(-2) x 1.73 m(-2) in the young], but remained within the normal range (> 90 ml x min(-2) x 1.73 m(-2)).",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[1.73·ml] / [(m)^2·(min)^2],90,181418,DB00999,Hydrochlorothiazide
,10379636,C(Cr),"In contrast, C(Cr) was even lower in healthy elderly subjects [95 (24) vs 121 (20) ml x min(-1) in the young], and the Cockroft-Gault clearance underestimated true glomerular filtration rate (GFR) even more seriously [74 (17) vs 122 (16) ml min(-1)].",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[ml] / [min],95,181419,DB00999,Hydrochlorothiazide
,10379636,C(Cr),"In contrast, C(Cr) was even lower in healthy elderly subjects [95 (24) vs 121 (20) ml x min(-1) in the young], and the Cockroft-Gault clearance underestimated true glomerular filtration rate (GFR) even more seriously [74 (17) vs 122 (16) ml min(-1)].",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[ml] / [min],121,181420,DB00999,Hydrochlorothiazide
,10379636,area under the curve (AUC),"For atenolol the mean area under the curve (AUC) was similar in both groups [3.16 (0.48) microg x h(-1) x ml(-1) in the elderly vs 3.01 (0.30) in the young], as was the mean maximal plasma concentration [0.42 (0.07) vs 0.44 (0.06) microg x ml(-1)], but the proportion of the drug excreted in urine was marginally (P < 0.025) lower in the elderly.",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[μg] / [h·ml],3.16,181421,DB00999,Hydrochlorothiazide
,10379636,area under the curve (AUC),"For atenolol the mean area under the curve (AUC) was similar in both groups [3.16 (0.48) microg x h(-1) x ml(-1) in the elderly vs 3.01 (0.30) in the young], as was the mean maximal plasma concentration [0.42 (0.07) vs 0.44 (0.06) microg x ml(-1)], but the proportion of the drug excreted in urine was marginally (P < 0.025) lower in the elderly.",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),,3.01,181422,DB00999,Hydrochlorothiazide
,10379636,maximal plasma concentration,"For atenolol the mean area under the curve (AUC) was similar in both groups [3.16 (0.48) microg x h(-1) x ml(-1) in the elderly vs 3.01 (0.30) in the young], as was the mean maximal plasma concentration [0.42 (0.07) vs 0.44 (0.06) microg x ml(-1)], but the proportion of the drug excreted in urine was marginally (P < 0.025) lower in the elderly.",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[μg] / [ml],0.42,181423,DB00999,Hydrochlorothiazide
,10379636,maximal plasma concentration,"For atenolol the mean area under the curve (AUC) was similar in both groups [3.16 (0.48) microg x h(-1) x ml(-1) in the elderly vs 3.01 (0.30) in the young], as was the mean maximal plasma concentration [0.42 (0.07) vs 0.44 (0.06) microg x ml(-1)], but the proportion of the drug excreted in urine was marginally (P < 0.025) lower in the elderly.",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[μg] / [ml],0.44,181424,DB00999,Hydrochlorothiazide
,9737817,steady-state maximum plasma concentration (Css(max),"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[ng] / [ml],145,181740,DB00999,Hydrochlorothiazide
,9737817,steady-state maximum plasma concentration (Css(max),"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[ng] / [ml],158,181741,DB00999,Hydrochlorothiazide
,9737817,time to maximum plasma concentration (t(max),"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),h,3.0,181742,DB00999,Hydrochlorothiazide
,9737817,time to maximum plasma concentration (t(max),"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),h,2.8,181743,DB00999,Hydrochlorothiazide
,9737817,area under the plasma concentration-time curve (AUCss,"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[h·ng] / [ml],688,181744,DB00999,Hydrochlorothiazide
,9737817,area under the plasma concentration-time curve (AUCss,"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[h·ng] / [ml],771,181745,DB00999,Hydrochlorothiazide
,9737817,oral clearance (Cl(oral),"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[l] / [h],96.2,181746,DB00999,Hydrochlorothiazide
,9737817,oral clearance (Cl(oral),"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[l] / [h],88.0,181747,DB00999,Hydrochlorothiazide
,9737817,elimination half-life (t(1/2),"Coadministered hydrochlorothiazide did not significantly (p > 0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (Css(max); 145 versus 158 ng mL(-1), respectively), time to maximum plasma concentration (t(max); 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUCss; 688 versus 771 ng x h mL(-1)), oral clearance (Cl(oral); 96.2 versus 88.0 L h(-1)), or elimination half-life (t(1/2); 5.2 versus 5.2 h).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),h,5.2,181748,DB00999,Hydrochlorothiazide
,9737817,Css(max),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[ng] / [ml],221,181749,DB00999,Hydrochlorothiazide
,9737817,Css(max),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[ng] / [ml],288,181750,DB00999,Hydrochlorothiazide
,9737817,t(max),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),h,1.8,181751,DB00999,Hydrochlorothiazide
,9737817,t(max),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),h,2.0,181752,DB00999,Hydrochlorothiazide
,9737817,AUCss,"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[h·ng] / [ml],1194,181753,DB00999,Hydrochlorothiazide
,9737817,AUCss,"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[h·ng] / [ml],1247,181754,DB00999,Hydrochlorothiazide
,9737817,Cl(oral),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[l] / [h],22.4,181755,DB00999,Hydrochlorothiazide
,9737817,Cl(oral),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[l] / [h],21.2,181756,DB00999,Hydrochlorothiazide
,9737817,t(1/2),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),h,9.8,181757,DB00999,Hydrochlorothiazide
,9737817,t(1/2),"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),h,9.6,181758,DB00999,Hydrochlorothiazide
,9737817,renal,"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[l] / [h],15.5,181759,DB00999,Hydrochlorothiazide
,9737817,Cl,"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[l] / [h],15.5,181760,DB00999,Hydrochlorothiazide
,9737817,Cl,"Similarly, administration of diltiazem did not significantly (p > 0.05) influence hydrochlorothiazide (alone versus combination) Css(max) (221 versus 288 ng mL(-1)), t(max) (1.8 versus 2.0 h), AUCss (1194 versus 1247 ng x h mL(-1)), Cl(oral) (22.4 versus 21.2 L h(-1)); t(1/2) (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h(-1)).",Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737817/),[l] / [h],15.2,181761,DB00999,Hydrochlorothiazide
,17331816,flow rate,"After a simple protein precipitation using acetonitrile, the analytes were separated on a Zorbax SB-Aq C18 column using acetonitrile-10mM ammonium acetate (60:40, v/v, pH 4.5) as mobile phase at a flow rate of 1.2 mL/min.",A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331816/),[ml] / [min],1.2,182489,DB00999,Hydrochlorothiazide
,26839805,flow rate,"After solid phase extraction (SPE), analytes and ISs were separated on an Agilent Poroshell 120, EC-C18 (50 mm × 4.6 mm, i.d., 2.7 μm) column with a mobile phase consisting of methanol/water (85:15, v/v) containing 5 mmol/L ammonium formate and 0.1% formic acid at a flow rate of 0.4 mL/min.","Simultaneous Determination and Pharmacokinetic Study of Losartan, Losartan Carboxylic Acid, Ramipril, Ramiprilat, and Hydrochlorothiazide in Rat Plasma by a Liquid Chromatography/Tandem Mass Spectrometry Method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26839805/),[ml] / [min],0.4,182648,DB00999,Hydrochlorothiazide
,18307734,bioavailability,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),%,2.6 and 5.0,185713,DB00999,Hydrochlorothiazide
,18307734,IC50,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),[nM] / [l],0.6,185714,DB00999,Hydrochlorothiazide
,18307734,plasma half-life,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),h,23-36,185715,DB00999,Hydrochlorothiazide
,11249553,elimination half-life,"The elimination half-life comes to about 7-8 h, valsartan is metabolised to a negligible extent and most of the drug is excreted via the faeces.",Valsartan: a novel angiotensin type 1 receptor antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249553/),h,7-8,190430,DB00999,Hydrochlorothiazide
,32371763,entrapment efficiencies,"The entrapment efficiencies ranged from 44 ± 2.1, 32.2 ± 4 and 40.5 ± 2.6% for amlodipine, hydrochlorothiazide and CNDT, respectively.",Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32371763/),%,44,195599,DB00999,Hydrochlorothiazide
,32371763,entrapment efficiencies,"The entrapment efficiencies ranged from 44 ± 2.1, 32.2 ± 4 and 40.5 ± 2.6% for amlodipine, hydrochlorothiazide and CNDT, respectively.",Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32371763/),%,32.2,195600,DB00999,Hydrochlorothiazide
,32371763,entrapment efficiencies,"The entrapment efficiencies ranged from 44 ± 2.1, 32.2 ± 4 and 40.5 ± 2.6% for amlodipine, hydrochlorothiazide and CNDT, respectively.",Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32371763/),%,40.5,195601,DB00999,Hydrochlorothiazide
,8223839,Cmax,"The controlled-release formulation gave less variable plasma metoprolol concentrations, Cmax 138 nmol.l-1 and Cmin 74 nmol.l-1, whereas for the conventional formulation the mean Cmax of metoprolol was 629 nmol.l-1 and the Cmin 20 nmol.l-1.",The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223839/),[nM] / [l],138,196853,DB00999,Hydrochlorothiazide
,8223839,Cmin,"The controlled-release formulation gave less variable plasma metoprolol concentrations, Cmax 138 nmol.l-1 and Cmin 74 nmol.l-1, whereas for the conventional formulation the mean Cmax of metoprolol was 629 nmol.l-1 and the Cmin 20 nmol.l-1.",The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223839/),[nM] / [l],74,196854,DB00999,Hydrochlorothiazide
,8223839,Cmax,"The controlled-release formulation gave less variable plasma metoprolol concentrations, Cmax 138 nmol.l-1 and Cmin 74 nmol.l-1, whereas for the conventional formulation the mean Cmax of metoprolol was 629 nmol.l-1 and the Cmin 20 nmol.l-1.",The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223839/),[nM] / [l],629,196855,DB00999,Hydrochlorothiazide
,8223839,Cmin,"The controlled-release formulation gave less variable plasma metoprolol concentrations, Cmax 138 nmol.l-1 and Cmin 74 nmol.l-1, whereas for the conventional formulation the mean Cmax of metoprolol was 629 nmol.l-1 and the Cmin 20 nmol.l-1.",The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223839/),[nM] / [l],20,196856,DB00999,Hydrochlorothiazide
,8223839,relative systemic availability,"Despite lower relative systemic availability (68%) for metoprolol from the controlled-release formulation and a smaller AUC, metoprolol from the controlled-release formulation produced a greater total effect, calculated as the area under the curve of the effect on exercise heart rate vs. time (303 vs. 259%.h; P < 0.05).",The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223839/),%,68,196857,DB00999,Hydrochlorothiazide
,7104466,urinary recovery,"Mean urinary recovery from 50, 100, and 250 mg doses was, respectively, 28.3, 47.0 and 83.3 mg, representing 56.4, 47.0, and 33.3 per cent of the administered dose.","Bioavailability of chlorothiazide from 50, 100, and 250 MG solution doses. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104466/),mg,28.3,198250,DB00999,Hydrochlorothiazide
,7104466,urinary recovery,"Mean urinary recovery from 50, 100, and 250 mg doses was, respectively, 28.3, 47.0 and 83.3 mg, representing 56.4, 47.0, and 33.3 per cent of the administered dose.","Bioavailability of chlorothiazide from 50, 100, and 250 MG solution doses. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104466/),mg,47.0,198251,DB00999,Hydrochlorothiazide
,7104466,urinary recovery,"Mean urinary recovery from 50, 100, and 250 mg doses was, respectively, 28.3, 47.0 and 83.3 mg, representing 56.4, 47.0, and 33.3 per cent of the administered dose.","Bioavailability of chlorothiazide from 50, 100, and 250 MG solution doses. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104466/),mg,83,198252,DB00999,Hydrochlorothiazide
,7104466,urinary recovery,"Mean urinary recovery from 50, 100, and 250 mg doses was, respectively, 28.3, 47.0 and 83.3 mg, representing 56.4, 47.0, and 33.3 per cent of the administered dose.","Bioavailability of chlorothiazide from 50, 100, and 250 MG solution doses. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104466/),%,56.4,198253,DB00999,Hydrochlorothiazide
,7104466,urinary recovery,"Mean urinary recovery from 50, 100, and 250 mg doses was, respectively, 28.3, 47.0 and 83.3 mg, representing 56.4, 47.0, and 33.3 per cent of the administered dose.","Bioavailability of chlorothiazide from 50, 100, and 250 MG solution doses. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104466/),%,47.0,198254,DB00999,Hydrochlorothiazide
,7104466,urinary recovery,"Mean urinary recovery from 50, 100, and 250 mg doses was, respectively, 28.3, 47.0 and 83.3 mg, representing 56.4, 47.0, and 33.3 per cent of the administered dose.","Bioavailability of chlorothiazide from 50, 100, and 250 MG solution doses. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104466/),%,33.3,198255,DB00999,Hydrochlorothiazide
,17119933,analysis time,"The analysis time for each sample was 4 min, and more than 300 samples could be analyzed in one day by running the system overnight.","Simultaneous determination of losartan, EXP-3174 and hydrochlorothiazide in plasma via fully automated 96-well-format-based solid-phase extraction and liquid chromatography-negative electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17119933/),min,4,203124,DB00999,Hydrochlorothiazide
,21069958,m/z,The target ions were m/z 163.15 for CA and m/z 295.95 for IS.,LC-MS determination and pharmacokinetics of p-coumaric acid in rat plasma after oral administration of p-coumaric acid and freeze-dried red wine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21069958/),,163.15,215522,DB00999,Hydrochlorothiazide
,21069958,m/z,The target ions were m/z 163.15 for CA and m/z 295.95 for IS.,LC-MS determination and pharmacokinetics of p-coumaric acid in rat plasma after oral administration of p-coumaric acid and freeze-dried red wine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21069958/),,295.95,215523,DB00999,Hydrochlorothiazide
,11404027,absolute bioavailability,The absolute bioavailability of the drug from the liquisolid tablets was 15% higher than that from the commercial one.,In vivo evaluation of hydrochlorothiazide liquisolid tablets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11404027/),%,15,219656,DB00999,Hydrochlorothiazide
,27469324,Systemic plasma clearance,"Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine).",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[ml] / [kg·min],1.1,220371,DB00999,Hydrochlorothiazide
,27469324,Systemic plasma clearance,"Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine).",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[ml] / [kg·min],37.4,220372,DB00999,Hydrochlorothiazide
,27469324,Volume of distribution,Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide.,Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[l] / [kg],0.7,220373,DB00999,Hydrochlorothiazide
,27469324,Volume of distribution,Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide.,Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[l] / [kg],3.2,220374,DB00999,Hydrochlorothiazide
,27469324,hepatocellularity,"The hepatocellularity for minipig was determined as 124 Mcells/g liver, similar to the values reported for human.",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[Mcells] / [g],124,220375,DB00999,Hydrochlorothiazide
,25459938,Cmax,The study indicated that 9.5% of free form of fidarestat may be pharmacologically active and the Cmax for free fidarestat was found to be 80.30 ± 6.78 ng/mL.,"Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatography-high resolution mass spectrometry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459938/),[ng] / [ml],80.30,223350,DB00999,Hydrochlorothiazide
,25459938,AUC0-t,"The AUC0-t and AUC0-∞ were found to be 185.46 ± 32 and 195.92 ± 15.06 ng h/mL, respectively.","Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatography-high resolution mass spectrometry. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459938/),[h·ng] / [ml],185.46,223351,DB00999,Hydrochlorothiazide
,25459938,AUC0-∞,"The AUC0-t and AUC0-∞ were found to be 185.46 ± 32 and 195.92 ± 15.06 ng h/mL, respectively.","Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatography-high resolution mass spectrometry. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459938/),[h·ng] / [ml],195.92,223352,DB00999,Hydrochlorothiazide
,31467909,flow rate,The flow rate was 0.3 mL/min.,A High Throughput HPLC-MS/MS Method for Antihypertensive Drugs Determination in Plasma and Its Application on Pharmacokinetic Interaction Study with Shuxuetong Injection in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31467909/),[ml] / [min],0.3,224280,DB00999,Hydrochlorothiazide
,7711419,Cmax,"For oxipurinol, mean Cmax was not altered on hydrochlorothiazide treatment (13.8 +/- 1.4 micrograms/ml and 14.7 +/- 2.6 micrograms/ml, respectively); mean AUC0-24 was 259 and 290 micrograms h-1 ml-1, respectively.","Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711419/),[μg] / [ml],13.8,229257,DB00999,Hydrochlorothiazide
,7711419,Cmax,"For oxipurinol, mean Cmax was not altered on hydrochlorothiazide treatment (13.8 +/- 1.4 micrograms/ml and 14.7 +/- 2.6 micrograms/ml, respectively); mean AUC0-24 was 259 and 290 micrograms h-1 ml-1, respectively.","Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711419/),[μg] / [ml],14.7,229258,DB00999,Hydrochlorothiazide
,7711419,AUC0-24,"For oxipurinol, mean Cmax was not altered on hydrochlorothiazide treatment (13.8 +/- 1.4 micrograms/ml and 14.7 +/- 2.6 micrograms/ml, respectively); mean AUC0-24 was 259 and 290 micrograms h-1 ml-1, respectively.","Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711419/),[μg] / [h·ml],259,229259,DB00999,Hydrochlorothiazide
,7711419,AUC0-24,"For oxipurinol, mean Cmax was not altered on hydrochlorothiazide treatment (13.8 +/- 1.4 micrograms/ml and 14.7 +/- 2.6 micrograms/ml, respectively); mean AUC0-24 was 259 and 290 micrograms h-1 ml-1, respectively.","Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711419/),[μg] / [h·ml],290,229260,DB00999,Hydrochlorothiazide
,22651563,run time,"The advantages of the described technique included a single method with a shorter run time (2.5 min), simple extraction technique, LLOQ of 1 ng/ml for CAN and 2 ng/ml for HCTZ and lower sample volume (0.10 ml), which overcomes drawbacks of two single methods for each analyte, such as higher analysis time, LOQ and sample volume, as in previously published methods.",LC-MS/MS method for simultaneous estimation of candesartan and hydrochlorothiazide in human plasma and its use in clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22651563/),min,2.5,231161,DB00999,Hydrochlorothiazide
,7062255,half-lives,"The pharmacokinetics of hydrochlorothiazide in plasma could be described in terms of a triexponential function, and the mean drug half-lives determined from the three exponents were 1.0, 2.2, and 9.0 hr.",Pharmacokinetics of hydrochlorothiazide in fasted and nonfasted subjects: a comparison of plasma level and urinary excretion methods. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062255/),h,1.0,233682,DB00999,Hydrochlorothiazide
,7062255,half-lives,"The pharmacokinetics of hydrochlorothiazide in plasma could be described in terms of a triexponential function, and the mean drug half-lives determined from the three exponents were 1.0, 2.2, and 9.0 hr.",Pharmacokinetics of hydrochlorothiazide in fasted and nonfasted subjects: a comparison of plasma level and urinary excretion methods. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062255/),h,2.2,233683,DB00999,Hydrochlorothiazide
,7062255,half-lives,"The pharmacokinetics of hydrochlorothiazide in plasma could be described in terms of a triexponential function, and the mean drug half-lives determined from the three exponents were 1.0, 2.2, and 9.0 hr.",Pharmacokinetics of hydrochlorothiazide in fasted and nonfasted subjects: a comparison of plasma level and urinary excretion methods. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062255/),h,9.0,233684,DB00999,Hydrochlorothiazide
,7062255,u,"Mean 48-hr urinary recovery of hydrochlorothiazide was 70.5% of the dose in nonfasted subjects, and 73.5 and 75.0% of the dose in fasted subjects receiving the drug with 20 and 250 ml of water, respectively.",Pharmacokinetics of hydrochlorothiazide in fasted and nonfasted subjects: a comparison of plasma level and urinary excretion methods. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062255/),,70,233685,DB00999,Hydrochlorothiazide
,7062255,u,"Mean 48-hr urinary recovery of hydrochlorothiazide was 70.5% of the dose in nonfasted subjects, and 73.5 and 75.0% of the dose in fasted subjects receiving the drug with 20 and 250 ml of water, respectively.",Pharmacokinetics of hydrochlorothiazide in fasted and nonfasted subjects: a comparison of plasma level and urinary excretion methods. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062255/),,73,233686,DB00999,Hydrochlorothiazide
,7062255,u,"Mean 48-hr urinary recovery of hydrochlorothiazide was 70.5% of the dose in nonfasted subjects, and 73.5 and 75.0% of the dose in fasted subjects receiving the drug with 20 and 250 ml of water, respectively.",Pharmacokinetics of hydrochlorothiazide in fasted and nonfasted subjects: a comparison of plasma level and urinary excretion methods. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062255/),,75,233687,DB00999,Hydrochlorothiazide
,465277,half-life,"The average half-life, 4.4 +/- 0.9 h, is about the same as previously observed for separate doses of this drug.",Bioavailability and disposition of metoprolol and hydrochlorothiazide combined in one tablet and of separate doses of hydrochlorothiazide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/465277/),h,4.4,237730,DB00999,Hydrochlorothiazide
,1665181,peak serum levels,"When given alone, peak serum levels of lisinopril (attained 6-8 hours post dose) were 44 ng/ml.",The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1665181/),[ng] / [ml],44,238465,DB00999,Hydrochlorothiazide
,1665181,Urinary recovery,Urinary recovery was 17.6% of the dose.,The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1665181/),,17,238466,DB00999,Hydrochlorothiazide
,1665181,peak serum concentration,"Dosing with hydrochlorothiazide alone resulted in a mean peak serum concentration of 53 ng/ml, 2-6 hours post dose.",The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1665181/),[ng] / [ml],53,238467,DB00999,Hydrochlorothiazide
,19433973,first-order elimination half-life,"Metformin concentrations decreased to 97 microg/mL 28 hours after the ingestion on CVVH, with a first-order elimination half-life of 11.3 hours (r(2) = 0.99) and a clearance of 56.2 mL/min.",The MALAdy of metformin poisoning: Is CVVH the cure? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19433973/),h,11.3,239277,DB00999,Hydrochlorothiazide
,19433973,clearance,"Metformin concentrations decreased to 97 microg/mL 28 hours after the ingestion on CVVH, with a first-order elimination half-life of 11.3 hours (r(2) = 0.99) and a clearance of 56.2 mL/min.",The MALAdy of metformin poisoning: Is CVVH the cure? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19433973/),[ml] / [min],56.2,239278,DB00999,Hydrochlorothiazide
,22122818,maximum plasma concentration (C(max)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[ng] / [ml],168,247743,DB00999,Hydrochlorothiazide
,22122818,maximum plasma concentration (C(max)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[ng] / [ml],121,247744,DB00999,Hydrochlorothiazide
,22122818,maximum plasma concentration (C(max)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[ng] / [ml],418,247745,DB00999,Hydrochlorothiazide
,22122818,exposure (AUC(0-48 h)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[h·ng] / [ml],"1,160",247746,DB00999,Hydrochlorothiazide
,22122818,exposure (AUC(0-48 h)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[h·ng] / [ml],955,247747,DB00999,Hydrochlorothiazide
,22122818,exposure (AUC(0-48 h)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[h·ng] / [ml],"2,801",247748,DB00999,Hydrochlorothiazide
,18611061,absolute bioavailability,The absolute bioavailability of aliskiren is 2.6%.,Clinical pharmacokinetics and pharmacodynamics of aliskiren. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611061/),%,2.6,252071,DB00999,Hydrochlorothiazide
,18611061,accumulation factor,"Steady-state plasma concentrations of aliskiren are reached after 7-8 days of once-daily dosing, and the accumulation factor for aliskiren is approximately 2.",Clinical pharmacokinetics and pharmacodynamics of aliskiren. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611061/),,2,252072,DB00999,Hydrochlorothiazide
,4026929,Plasma half-life,Plasma half-life values were 1 h for phase alpha and 17 h for phase beta.,Single-dose pharmacokinetics of fenquizone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026929/),h,1,258596,DB00999,Hydrochlorothiazide
,4026929,Plasma half-life,Plasma half-life values were 1 h for phase alpha and 17 h for phase beta.,Single-dose pharmacokinetics of fenquizone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026929/),h,17,258597,DB00999,Hydrochlorothiazide
,4026929,half-life,The half-life calculated from urinary concentrations was 18 h.,Single-dose pharmacokinetics of fenquizone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026929/),h,18,258598,DB00999,Hydrochlorothiazide
,4026929,apparent distribution volume for phase beta,"The apparent distribution volume for phase beta was 686 l; renal clearance was 220 ml/min, and the absorption constant (Ka) was 1055 h-1.",Single-dose pharmacokinetics of fenquizone in healthy volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026929/),l,686,258599,DB00999,Hydrochlorothiazide
,4026929,renal clearance,"The apparent distribution volume for phase beta was 686 l; renal clearance was 220 ml/min, and the absorption constant (Ka) was 1055 h-1.",Single-dose pharmacokinetics of fenquizone in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026929/),[ml] / [min],220,258600,DB00999,Hydrochlorothiazide
,4026929,absorption constant (Ka),"The apparent distribution volume for phase beta was 686 l; renal clearance was 220 ml/min, and the absorption constant (Ka) was 1055 h-1.",Single-dose pharmacokinetics of fenquizone in healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026929/),1/[h],1055,258601,DB00999,Hydrochlorothiazide
,17080507,recovery,"The extraction procedure yielded extremely clean extracts with a recovery of 107.44 and 98.93% for pravastatin and IS, respectively.",A rapid and specific approach for direct measurement of pravastatin concentration in plasma by LC-MS/MS employing solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080507/),%,107.44,259228,DB00999,Hydrochlorothiazide
,17080507,recovery,"The extraction procedure yielded extremely clean extracts with a recovery of 107.44 and 98.93% for pravastatin and IS, respectively.",A rapid and specific approach for direct measurement of pravastatin concentration in plasma by LC-MS/MS employing solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080507/),%,98.93,259229,DB00999,Hydrochlorothiazide
,17080507,total run time,The method is simple and reliable with a total run time of 3 min.,A rapid and specific approach for direct measurement of pravastatin concentration in plasma by LC-MS/MS employing solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080507/),min,3,259230,DB00999,Hydrochlorothiazide
,7898090,half-life,"We showed that single oral doses of cilazapril 4 mg, captopril 25 mg, or enalapril 10 mg shifted the angiotensin I dose-effect curve to the right and determined a pharmacologic half-life of about 4 h for cilazapril.",Review of studies on the clinical pharmacodynamics of cilazapril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7898090/),h,4,262739,DB00999,Hydrochlorothiazide
,7898090,apparent Ki dose,The dose representing 50% inhibition of ACE activity (apparent Ki dose) was about 0.6 mg 3 h after cilazapril administration.,Review of studies on the clinical pharmacodynamics of cilazapril. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7898090/),mg,0.6,262740,DB00999,Hydrochlorothiazide
,16029066,terminal half-life,E 3174 is 10- to 40-fold more potent than its parent compound and its estimated terminal half-life ranges from 6 to 9 hours.,Clinical pharmacokinetics of losartan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029066/),h,6 to 9,263266,DB00999,Hydrochlorothiazide
,8068579,elimination half-life,"After oral administration the maximum concentration of moxonidine is reached in about 1 hour, and elimination half-life is 2.5 hours, prolonged by renal insufficiency.",Clinical experience with moxonidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068579/),h,2.5,267059,DB00999,Hydrochlorothiazide
,2708546,Clearance of pinacidil (Clp,Clearance of pinacidil (Clp = Dose/AUC) was 31 L/hr in patients younger than 45 years and 27 L/hr in those older than 60.,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],31,267136,DB00999,Hydrochlorothiazide
,2708546,Clearance of pinacidil (Clp,Clearance of pinacidil (Clp = Dose/AUC) was 31 L/hr in patients younger than 45 years and 27 L/hr in those older than 60.,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],27,267137,DB00999,Hydrochlorothiazide
,2708546,Clp,Clp was significantly smaller in white patients compared with other races (Clp = 28 vs. 34 L/hr).,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],28,267138,DB00999,Hydrochlorothiazide
,2708546,Clp,Clp was significantly smaller in white patients compared with other races (Clp = 28 vs. 34 L/hr).,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],34,267139,DB00999,Hydrochlorothiazide
,2708546,Clp,Clp was significantly less in patients taking hydrochlorothiazide (27 vs. 31 L/hr) and greater in smokers (33 vs. 29 L/hr).,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],27,267140,DB00999,Hydrochlorothiazide
,2708546,Clp,Clp was significantly less in patients taking hydrochlorothiazide (27 vs. 31 L/hr) and greater in smokers (33 vs. 29 L/hr).,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],31,267141,DB00999,Hydrochlorothiazide
,2708546,Clp,Clp was significantly less in patients taking hydrochlorothiazide (27 vs. 31 L/hr) and greater in smokers (33 vs. 29 L/hr).,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],33,267142,DB00999,Hydrochlorothiazide
,2708546,Clp,Clp was significantly less in patients taking hydrochlorothiazide (27 vs. 31 L/hr) and greater in smokers (33 vs. 29 L/hr).,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],29,267143,DB00999,Hydrochlorothiazide
,15856489,m/z,"The mass transitions m/z 296.1 solidus in circle 205.0 and m/z 407.2 solidus in circle 184.9 were used to measure I and II, respectively.",Sensitive liquid chromatography-tandem mass spectrometry method for quantification of hydrochlorothiazide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15856489/),,407.2,268670,DB00999,Hydrochlorothiazide
,15856489,run time,A run time of 2.5 min for each sample made it possible to analyze a throughput of more than 400 human plasma samples per day.,Sensitive liquid chromatography-tandem mass spectrometry method for quantification of hydrochlorothiazide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15856489/),min,2.5,268671,DB00999,Hydrochlorothiazide
,19940337,flow rate,The mobile phase consisted of HPLC Grade Acetonitrile: 2 mM Ammonium acetate (90 : 10 v / v) at a flow rate of 0.5 mL min(-1).,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),[ml] / [min],0.5,270599,DB00999,Hydrochlorothiazide
,19940337,total chromatographic runtime,The total chromatographic runtime was 2.5 minutes.,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),min,2.5,270600,DB00999,Hydrochlorothiazide
,19940337,m/z,The mass transition ion pair has been followed as m/z 296.10/205.00 for HCTZ and 266.10/223.10 for Zidovudine.,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),,296.10,270601,DB00999,Hydrochlorothiazide
,19940337,m/z,The mass transition ion pair has been followed as m/z 296.10/205.00 for HCTZ and 266.10/223.10 for Zidovudine.,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),,205.00,270602,DB00999,Hydrochlorothiazide
,19940337,m/z,The mass transition ion pair has been followed as m/z 296.10/205.00 for HCTZ and 266.10/223.10 for Zidovudine.,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),,266.10,270603,DB00999,Hydrochlorothiazide
,19940337,m/z,The mass transition ion pair has been followed as m/z 296.10/205.00 for HCTZ and 266.10/223.10 for Zidovudine.,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),,223.10,270604,DB00999,Hydrochlorothiazide
,19940337,overall recovery,The mean overall recovery of HCTZ was 66.40% with a precision of 2.44%.,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),%,66.40,270605,DB00999,Hydrochlorothiazide
,19940337,recovery,The mean recovery of internal standard (Zidovudine) was 63.62% with a precision ranging from 2.06% to 5.40%.,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),%,63.62,270606,DB00999,Hydrochlorothiazide
,26047011,entrapment efficiencies,"The candidate drugs encapsulated inside PLGA showed entrapment efficiencies ranging from 30%, 33.5% and 32% for hydrochlorothiazide, candesartan and amlodipine respectively.","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),%,30,271417,DB00999,Hydrochlorothiazide
,26047011,entrapment efficiencies,"The candidate drugs encapsulated inside PLGA showed entrapment efficiencies ranging from 30%, 33.5% and 32% for hydrochlorothiazide, candesartan and amlodipine respectively.","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),%,33.5,271418,DB00999,Hydrochlorothiazide
,26047011,entrapment efficiencies,"The candidate drugs encapsulated inside PLGA showed entrapment efficiencies ranging from 30%, 33.5% and 32% for hydrochlorothiazide, candesartan and amlodipine respectively.","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),%,32,271419,DB00999,Hydrochlorothiazide
,26047011,MRT,"In pharmacokinetic analysis a sustained-release for 6 days and significant increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of amlodipine, hydrochlorothiazide and candesartan changed from 8.9 to 80.59 hours, 11 to 69.20 hours and 9 to 101.49 hours respectively].","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),h,8.9 to 80.59,271420,DB00999,Hydrochlorothiazide
,26047011,MRT,"In pharmacokinetic analysis a sustained-release for 6 days and significant increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of amlodipine, hydrochlorothiazide and candesartan changed from 8.9 to 80.59 hours, 11 to 69.20 hours and 9 to 101.49 hours respectively].","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),h,11 to 69.20,271421,DB00999,Hydrochlorothiazide
,26047011,MRT,"In pharmacokinetic analysis a sustained-release for 6 days and significant increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of amlodipine, hydrochlorothiazide and candesartan changed from 8.9 to 80.59 hours, 11 to 69.20 hours and 9 to 101.49 hours respectively].","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),h,9 to 101.49,271422,DB00999,Hydrochlorothiazide
